<!DOCTYPE article PUBLIC "-//NLM//DTD Journal Archiving and Interchange DTD v2.3 20070202//EN" "archivearticle.dtd"><article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article" xml:lang="EN"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">PLoS ONE</journal-id><journal-id journal-id-type="publisher-id">plos</journal-id><journal-id journal-id-type="pmc">plosone</journal-id><journal-title>PLoS ONE</journal-title><issn pub-type="epub">1932-6203</issn><publisher><publisher-name>Public Library of Science</publisher-name><publisher-loc>San Francisco, USA</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">19238203</article-id><article-id pub-id-type="pmc">2641016</article-id><article-id pub-id-type="publisher-id">09-PONE-RA-07989</article-id><article-id pub-id-type="doi">10.1371/journal.pone.0004559</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="Discipline"><subject>Biotechnology</subject><subject>Cell Biology/Cell Signaling</subject><subject>Cell Biology/Gene Expression</subject><subject>Biotechnology</subject><subject>Cell Biology/Cell Signaling</subject><subject>Cell Biology/Gene Expression</subject></subj-group></article-categories><title-group><article-title>RNAi Methodologies for the Functional Study of Signaling Molecules</article-title><alt-title alt-title-type="running-head">Gene Silencing</alt-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Lee</surname><given-names>Gwang</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref><xref ref-type="aff" rid="aff2"><sup>2</sup></xref></contrib><contrib contrib-type="author"><name><surname>Santat</surname><given-names>Leah A.</given-names></name><xref ref-type="aff" rid="aff3"><sup>3</sup></xref></contrib><contrib contrib-type="author"><name><surname>Chang</surname><given-names>Mi Sook</given-names></name><xref ref-type="aff" rid="aff3"><sup>3</sup></xref></contrib><contrib contrib-type="author"><name><surname>Choi</surname><given-names>Sangdun</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref><xref ref-type="aff" rid="aff4"><sup>4</sup></xref><xref ref-type="corresp" rid="cor1"><sup>&#x0002a;</sup></xref></contrib></contrib-group><aff id="aff1"><label>1</label><addr-line>Department of Molecular Science and Technology, College of Natural Science, Ajou University, Suwon, Korea</addr-line></aff><aff id="aff2"><label>2</label><addr-line>Institute for Medical Sciences, College of Natural Science, Ajou University, Suwon, Korea</addr-line></aff><aff id="aff3"><label>3</label><addr-line>Molecular Biology Laboratory, Alliance for Cellular Signaling, Division of Biology, California Institute of Technology, Pasadena, California, United States of America</addr-line></aff><aff id="aff4"><label>4</label><addr-line>Department of Biological Sciences, College of Natural Science, Ajou University, Suwon, Korea</addr-line></aff><contrib-group><contrib contrib-type="editor"><name><surname>Means</surname><given-names>Terry</given-names></name><role>Editor</role><xref ref-type="aff" rid="edit1"/></contrib></contrib-group><aff id="edit1">Massachusetts General Hospital/Harvard University, United States of America</aff><author-notes><corresp id="cor1">&#x0002a; E-mail: <email>sangdunchoi@ajou.ac.kr</email></corresp><fn fn-type="con"><p>Conceived and designed the experiments: GL SC. Performed the experiments: LAS MSC. Wrote the paper: GL SC.</p></fn></author-notes><pub-date pub-type="collection"><year>2009</year></pub-date><pub-date pub-type="epub"><day>24</day><month>2</month><year>2009</year></pub-date><volume>4</volume><issue>2</issue><elocation-id>e4559</elocation-id><history><date date-type="received"><day>2</day><month>1</month><year>2009</year></date><date date-type="accepted"><day>13</day><month>1</month><year>2009</year></date></history><copyright-statement>Lee et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.</copyright-statement><copyright-year>2009</copyright-year><abstract><p>RNA interference (RNAi) was investigated with the aim of achieving gene silencing with diverse RNAi platforms that include small interfering RNA (siRNA), short hairpin RNA (shRNA) and antisense oligonucleotides (ASO). Different versions of each system were used to silence the expression of specific subunits of the heterotrimeric signal transducing G-proteins, G alpha i2 and G beta 2, in the RAW 264.7 murine macrophage cell line. The specificity of the different RNA interference (RNAi) platforms was assessed by DNA microarray analysis. Reliable RNAi methodologies against the genes of interest were then developed and applied to functional studies of signaling networks. This study demonstrates a successful knockdown of target genes and shows the potential of RNAi for use in functional studies of signaling molecules.</p></abstract><counts><page-count count="10"/></counts></article-meta></front><body><sec id="s1"><title>Introduction</title><p>RNA interference (RNAi) has been widely used by animal cell biologists as a gene silencing tool to study the cellular effects generated by modulating the expression of individual genes <xref ref-type="bibr" rid="pone.0004559-Guo1">&#x0005b;1&#x0005d;</xref>, <xref ref-type="bibr" rid="pone.0004559-Hannon1">&#x0005b;2&#x0005d;</xref>, <xref ref-type="bibr" rid="pone.0004559-Hutvagner1">&#x0005b;3&#x0005d;</xref>, <xref ref-type="bibr" rid="pone.0004559-Sharp1">&#x0005b;4&#x0005d;</xref>, <xref ref-type="bibr" rid="pone.0004559-Hwang1">&#x0005b;5&#x0005d;</xref>, <xref ref-type="bibr" rid="pone.0004559-Hwang2">&#x0005b;6&#x0005d;</xref>. Expression can be reduced by introducing gene-specific double-stranded RNA (dsRNA) or single-stranded RNA (ssRNA) into a cell. Subsequently, the small RNA products generated from Drosha and/or Dicer-mediated dsRNA processing are delivered to the RNA-induced silencing complex (RISC), which is implicated in mRNA destruction and translational repression, and the RNA-induced transcriptional silencing complex (RITS), which is implicated in chromatin silencing <xref ref-type="bibr" rid="pone.0004559-Mello1">&#x0005b;7&#x0005d;</xref>, <xref ref-type="bibr" rid="pone.0004559-Bernstein1">&#x0005b;8&#x0005d;</xref>, <xref ref-type="bibr" rid="pone.0004559-Bernstein2">&#x0005b;9&#x0005d;</xref>.</p><p>However, difficulties remain in finding the best way to make RNAi work as a gene-specific silencing procedure for signaling studies. For example, dsRNA <xref ref-type="bibr" rid="pone.0004559-Alexopoulou1">&#x0005b;10&#x0005d;</xref> or ssRNA <xref ref-type="bibr" rid="pone.0004559-Heil1">&#x0005b;11&#x0005d;</xref>, <xref ref-type="bibr" rid="pone.0004559-Lund1">&#x0005b;12&#x0005d;</xref>, <xref ref-type="bibr" rid="pone.0004559-Diebold1">&#x0005b;13&#x0005d;</xref> can stimulate innate cytokine responses in mammals. Additionally, synthetic small interfering RNAs (siRNAs) formulated in nonviral delivery vehicles can be potent inducers of interferons and inflammatory cytokines in mice and humans <xref ref-type="bibr" rid="pone.0004559-Judge1">&#x0005b;14&#x0005d;</xref>. siRNAs can also mediate sequence-independent gene suppression and induce immune activation by signaling through toll-like receptor 3 (TLR3) <xref ref-type="bibr" rid="pone.0004559-Kariko1">&#x0005b;15&#x0005d;</xref>. A recent study showed that dsRNAs that are 21 nucleotides or longer are also involved in anti-angiogenic responses <xref ref-type="bibr" rid="pone.0004559-Kleinman1">&#x0005b;16&#x0005d;</xref>. These could significantly limit the application of RNAi and result in off-target effects and immuno-stimulation associated with the nucleic acid treatments. In order to develop reliable RNAi reagents, three different platforms were tested: small interfering RNA (siRNA), antisense oligonucleotide (ASO) and short hairpin RNA (shRNA). siRNA, ASO and shRNA were designed to knockdown the endogenous G protein alpha i2 (G&#x003b1;i2) or G protein beta 2 (G&#x003b2;2) gene in screens in RAW 264.7 murine macrophage-like cells. A series of gene expression profiling experiments and quantitative reverse transcriptase-polymerase chain reaction (QRT-PCR) analyses were carried out to assess both the specificity of the target gene knockdown and the functional studies of the targeted signaling molecules. G&#x003b1;i2 knockdown cells were tested to monitor the changes in signaling networks after treatment with different ligands, in this case lipopolysaccharide (LPS), Pam<sub>2</sub>CSK4 (Pam<sub>2</sub>) or prostaglandin E2 (PGE<sub>2</sub>).</p></sec><sec id="s2"><title>Results</title><sec id="s2a"><title>DNA Microarray and RT-PCR verification of expression of specific genes in RAW 264.7 cells</title><p>To develop a clear picture of the nature of the genes expressed in RAW 264.7 cells, Affymetrix GeneChip screening was performed, producing duplicate array data sets. Affymetrix Mouse 430 chips A and B were used to assess the gene expression of RAW 264.7 cells, mouse bone marrow derived macrophage (BMDM) cells and the mouse macrophage cell line, J774A.1. BMDM and the cell lines have &#x02018;Present Call&#x02019; gene elements ranging from 17K to 19K (data available at The Signaling Gateway: <ext-link ext-link-type="uri" xlink:href="http://www.signaling-gateway.org/data/micro/cgi-bin/micro.cgi?exptaffy">http://www.signaling-gateway.org/data/micro/cgi-bin/micro.cgi?exptaffy</ext-link>). <xref ref-type="table" rid="pone-0004559-t001">Table 1</xref> shows that a gene marked &#x02018;Present&#x02019; in the Affymetrix GeneChip data was almost always determined to be &#x02018;Present&#x02019; when measured using RT-PCR. To avoid any possible errors in the design of PCR primer sets, genes showing an &#x02018;Absent&#x02019; signal in RT-PCR during the first trial were verified using 2 to 3 alternative primer sets. Overall, approximately 5&#x00025; of the transcripts found to be present in the microarray were absent according to RT-PCR, and 30&#x02013;40&#x00025; of absent determinations according to the microarray were detected by RT-PCR (<xref ref-type="supplementary-material" rid="pone.0004559.s001">Table S1</xref>). However, in cases in which multiple probes existed on the chip (38&#x00025; of the probes), reproducible calls (P: Present or A: Absent) improve the odds of a correct result. The presence of G&#x003b1;i2 and G&#x003b2;2 mRNAs was verified using a DNA microarray and by a RT-PCR analysis (<xref ref-type="table" rid="pone-0004559-t001">Table 1</xref>).</p><table-wrap id="pone-0004559-t001" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0004559.t001</object-id><label>Table 1</label><caption><title>Expression of heterotrimeric G protein subunits and RGS proteins in RAW 264.7 cells, as assessed by Affymetrix GeneChips and RT-PCR (P: present, A: absent).</title></caption><graphic id="pone-0004559-t001-1" xlink:href="pone.0004559.t001"/><table frame="hsides" rules="groups" alternate-form-of="pone-0004559-t001-1"><colgroup span="1"><col align="left" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/></colgroup><thead><tr><td align="left" rowspan="1" colspan="1">Symbol</td><td align="left" rowspan="1" colspan="1">Gene Name</td><td align="left" rowspan="1" colspan="1">Affymetrix Calls</td><td align="left" rowspan="1" colspan="1">RT-PCR Results</td><td align="left" rowspan="1" colspan="1">Abundance</td><td align="left" rowspan="1" colspan="1">UMRR<xref ref-type="table-fn" rid="nt101">&#x0002a;</xref></td></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">Gnai1</td><td align="left" rowspan="1" colspan="1">G alpha i1 subunit</td><td align="left" rowspan="1" colspan="1">A</td><td align="left" rowspan="1" colspan="1">A</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">P</td></tr><tr><td align="left" rowspan="1" colspan="1">Gnai2</td><td align="left" rowspan="1" colspan="1">G alpha i2 subunit</td><td align="left" rowspan="1" colspan="1">P</td><td align="left" rowspan="1" colspan="1">P</td><td align="left" rowspan="1" colspan="1">high</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">Gnai3</td><td align="left" rowspan="1" colspan="1">G alpha i3 subunit</td><td align="left" rowspan="1" colspan="1">P</td><td align="left" rowspan="1" colspan="1">P</td><td align="left" rowspan="1" colspan="1">medium</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">Gna11</td><td align="left" rowspan="1" colspan="1">G alpha 11 subunit</td><td align="left" rowspan="1" colspan="1">P</td><td align="left" rowspan="1" colspan="1">P</td><td align="left" rowspan="1" colspan="1">medium</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">Gna14</td><td align="left" rowspan="1" colspan="1">G alpha 14 subunit</td><td align="left" rowspan="1" colspan="1">A,A</td><td align="left" rowspan="1" colspan="1">A</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">P</td></tr><tr><td align="left" rowspan="1" colspan="1">Gna15</td><td align="left" rowspan="1" colspan="1">G alpha 15/16 subunit</td><td align="left" rowspan="1" colspan="1">A</td><td align="left" rowspan="1" colspan="1">P</td><td align="left" rowspan="1" colspan="1">high</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">Gnaq</td><td align="left" rowspan="1" colspan="1">G alpha q subunit</td><td align="left" rowspan="1" colspan="1">P</td><td align="left" rowspan="1" colspan="1">P</td><td align="left" rowspan="1" colspan="1">high</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">Gnb1</td><td align="left" rowspan="1" colspan="1">G beta 1 subunit</td><td align="left" rowspan="1" colspan="1">P,A,P</td><td align="left" rowspan="1" colspan="1">P</td><td align="left" rowspan="1" colspan="1">high</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">Gnb2</td><td align="left" rowspan="1" colspan="1">G beta 2 subunit</td><td align="left" rowspan="1" colspan="1">P</td><td align="left" rowspan="1" colspan="1">P</td><td align="left" rowspan="1" colspan="1">medium</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">Gnb3</td><td align="left" rowspan="1" colspan="1">G beta 3 subunit</td><td align="left" rowspan="1" colspan="1">A</td><td align="left" rowspan="1" colspan="1">A</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">P</td></tr><tr><td align="left" rowspan="1" colspan="1">Gnb4</td><td align="left" rowspan="1" colspan="1">G beta 4 subunit</td><td align="left" rowspan="1" colspan="1">P</td><td align="left" rowspan="1" colspan="1">P</td><td align="left" rowspan="1" colspan="1">medium</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">Gnb5</td><td align="left" rowspan="1" colspan="1">G beta 5 subunit</td><td align="left" rowspan="1" colspan="1">A,P</td><td align="left" rowspan="1" colspan="1">P</td><td align="left" rowspan="1" colspan="1">high</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">Gng2</td><td align="left" rowspan="1" colspan="1">G gamma 2 subunit</td><td align="left" rowspan="1" colspan="1">P,A,P</td><td align="left" rowspan="1" colspan="1">P</td><td align="left" rowspan="1" colspan="1">low</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">Gng3</td><td align="left" rowspan="1" colspan="1">G gamma 3 subunit</td><td align="left" rowspan="1" colspan="1">A</td><td align="left" rowspan="1" colspan="1">A</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">P</td></tr><tr><td align="left" rowspan="1" colspan="1">Gng4</td><td align="left" rowspan="1" colspan="1">G gamma 4 subunit</td><td align="left" rowspan="1" colspan="1">A,A,A</td><td align="left" rowspan="1" colspan="1">A</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">A</td></tr><tr><td align="left" rowspan="1" colspan="1">Gng5</td><td align="left" rowspan="1" colspan="1">G gamma 5 subunit</td><td align="left" rowspan="1" colspan="1">P,P,A</td><td align="left" rowspan="1" colspan="1">P</td><td align="left" rowspan="1" colspan="1">medium</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">Gng7</td><td align="left" rowspan="1" colspan="1">G gamma 7 subunit</td><td align="left" rowspan="1" colspan="1">A</td><td align="left" rowspan="1" colspan="1">P</td><td align="left" rowspan="1" colspan="1">low</td><td align="left" rowspan="1" colspan="1">P</td></tr><tr><td align="left" rowspan="1" colspan="1">Gng8</td><td align="left" rowspan="1" colspan="1">G gamma 8 subunit</td><td align="left" rowspan="1" colspan="1">A</td><td align="left" rowspan="1" colspan="1">P</td><td align="left" rowspan="1" colspan="1">medium</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">Gng10</td><td align="left" rowspan="1" colspan="1">G gamma 10 subunit</td><td align="left" rowspan="1" colspan="1">P</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">Gng11</td><td align="left" rowspan="1" colspan="1">G gamma 11 subunit</td><td align="left" rowspan="1" colspan="1">A</td><td align="left" rowspan="1" colspan="1">P</td><td align="left" rowspan="1" colspan="1">medium</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">Gng12</td><td align="left" rowspan="1" colspan="1">G gamma 12 subunit</td><td align="left" rowspan="1" colspan="1">P</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">Gng13</td><td align="left" rowspan="1" colspan="1">G gamma 13 subunit</td><td align="left" rowspan="1" colspan="1">A</td><td align="left" rowspan="1" colspan="1">A</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">P</td></tr><tr><td align="left" rowspan="1" colspan="1">Gng14</td><td align="left" rowspan="1" colspan="1">G gamma 14 subunit</td><td align="left" rowspan="1" colspan="1">P</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">Rgs4</td><td align="left" rowspan="1" colspan="1">regulator of G protein signaling 4</td><td align="left" rowspan="1" colspan="1">A,A,A</td><td align="left" rowspan="1" colspan="1">A</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">P</td></tr><tr><td align="left" rowspan="1" colspan="1">Rgs7</td><td align="left" rowspan="1" colspan="1">regulator of G protein signaling 7</td><td align="left" rowspan="1" colspan="1">A</td><td align="left" rowspan="1" colspan="1">A</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">P</td></tr><tr><td align="left" rowspan="1" colspan="1">Rgs8</td><td align="left" rowspan="1" colspan="1">regulator of G protein signaling 8</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">P</td><td align="left" rowspan="1" colspan="1">medium</td><td align="left" rowspan="1" colspan="1">P</td></tr><tr><td align="left" rowspan="1" colspan="1">Rgs13</td><td align="left" rowspan="1" colspan="1">regulator of G protein signaling 13</td><td align="left" rowspan="1" colspan="1">A</td><td align="left" rowspan="1" colspan="1">P</td><td align="left" rowspan="1" colspan="1">low</td><td align="left" rowspan="1" colspan="1">P</td></tr><tr><td align="left" rowspan="1" colspan="1">Rgs16</td><td align="left" rowspan="1" colspan="1">regulator of G protein signaling 16</td><td align="left" rowspan="1" colspan="1">A,A,A</td><td align="left" rowspan="1" colspan="1">P</td><td align="left" rowspan="1" colspan="1">high</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">Rgs19</td><td align="left" rowspan="1" colspan="1">regulator of G protein signaling 19</td><td align="left" rowspan="1" colspan="1">P,P</td><td align="left" rowspan="1" colspan="1">P</td><td align="left" rowspan="1" colspan="1">high</td><td align="left" rowspan="1" colspan="1">P</td></tr></tbody></table><table-wrap-foot><fn id="nt101"><label>&#x0002a;</label><p>RT-PCR results in Universal Mouse Reference RNA (11 cell line mixture).</p></fn></table-wrap-foot></table-wrap></sec><sec id="s2b"><title>Establishment of cells lacking G&#x003b1;i2 and G&#x003b2;2 proteins</title><p>G protein coupled receptors are characterized by seven transmembrane domains, and ligands stimulating these receptors are diverse and include immuno-stimulating molecules. Heterotrimeric G proteins are composed of &#x003b1;, &#x003b2; and &#x003b3; subunits, with the G protein alpha subunits consisting of four families: G&#x003b1;i/o, G&#x003b1;s, G&#x003b1;q/11 and G&#x003b1;12/13. The G&#x003b1;i family is further characterized into G&#x003b1;i1, G&#x003b1;i2 and G&#x003b1;i3. G&#x003b1;i2 has been reported to inhibit the activities of types I, V, and VI adenylyl cyclase isoforms directly <xref ref-type="bibr" rid="pone.0004559-Grishina1">&#x0005b;17&#x0005d;</xref>. As G&#x003b1;i2 appears to be involved in a complex pattern of signaling <xref ref-type="bibr" rid="pone.0004559-Grishina1">&#x0005b;17&#x0005d;</xref>, <xref ref-type="bibr" rid="pone.0004559-Rudolph1">&#x0005b;18&#x0005d;</xref>, <xref ref-type="bibr" rid="pone.0004559-Pace1">&#x0005b;19&#x0005d;</xref>, <xref ref-type="bibr" rid="pone.0004559-Huang1">&#x0005b;20&#x0005d;</xref>, <xref ref-type="bibr" rid="pone.0004559-Lyons1">&#x0005b;21&#x0005d;</xref>, <xref ref-type="bibr" rid="pone.0004559-Sprang1">&#x0005b;22&#x0005d;</xref>, <xref ref-type="bibr" rid="pone.0004559-Watkins1">&#x0005b;23&#x0005d;</xref>, <xref ref-type="bibr" rid="pone.0004559-Zhang1">&#x0005b;24&#x0005d;</xref>, <xref ref-type="bibr" rid="pone.0004559-Bjursten1">&#x0005b;25&#x0005d;</xref>, <xref ref-type="bibr" rid="pone.0004559-Bjursten2">&#x0005b;26&#x0005d;</xref>, <xref ref-type="bibr" rid="pone.0004559-Baritono1">&#x0005b;27&#x0005d;</xref>, insight into its function was sought by silencing the G&#x003b1;i2 transcript. In addition, the G&#x003b2;2 subunits released upon activation of the heterotrimeric G protein activate specific effectors, and previous studies have shown it to be the primary beta subunit for certain G&#x003b1;i signaling pathways in macrophage cells <xref ref-type="bibr" rid="pone.0004559-Hwang1">&#x0005b;5&#x0005d;</xref>, <xref ref-type="bibr" rid="pone.0004559-Hwang2">&#x0005b;6&#x0005d;</xref>. Thus, G&#x003b2;2 was also targeted to test the RNAi mechanisms.</p><p>RAW 264.7 cells were transfected with siRNA or ASO against G&#x003b1;i2 or G&#x003b2;2. Western blot results (<xref ref-type="fig" rid="pone-0004559-g001">Figures 1A and B</xref>) showed a significant knockdown of the target gene in each of experiments. RAW cells were transfected using FuGENE6 (Roche Molecular Biochemicals, Indianapolis, IN) for ASO and Lipofectamine 2000 (Invitrogen, Carlsbad, CA) for siRNA. Cells were harvested at 72 hr post-transfection.</p><fig id="pone-0004559-g001" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0004559.g001</object-id><label>Figure 1</label><caption><title>Western blot analysis of (A) G&#x003b1;i2 and (B) G&#x003b2;2 proteins in shRNA, siRNA and ASO treated RAW 264.7 cells.</title><p>Two independent experiments are shown for the siRNA and ASO treatments. Blots from the shRNA-expressing lentiviral (LV) lines are representative of multiple samples taken over a 5-week period. Significant target gene knockdown is observed with all three platforms. UGIP: control lentivirus transfected cell line, UT: untreated, Mock: mock-treated. (C) Schematic diagram of the lentiviral construct used to generate shRNA expressing RAW 264.7 cell lines. The hairpin form of siRNA is expressed under the control of a mouse H1RNA polymerase III promoter. The vector also contains the enhanced GFP marker gene and the puromycin resistance gene (Puro) regulated by a UbiC promoter. IRES, internal ribosome entry site; FLAP, HIV-1 FLAP element; WRE, woodchuck hepatitis post- transcriptional regulatory element.</p></caption><graphic xlink:href="pone.0004559.g001"/></fig><p>Pseudotyped lentivirus carrying shRNA can be efficiently integrated into the chromosome, making it a good carrier for the delivery and sustained expression of shRNA <xref ref-type="bibr" rid="pone.0004559-Hwang1">&#x0005b;5&#x0005d;</xref>, <xref ref-type="bibr" rid="pone.0004559-Stewart1">&#x0005b;28&#x0005d;</xref>. Lentiviral vectors were constructed with expression cassettes that allowed the expression of antibiotic selection markers (e.g., puromycin) in order to identify and enrich the fraction of transduced cells (<xref ref-type="fig" rid="pone-0004559-g001">Figure 1C</xref>). Cells were infected with a lentivirus containing a previously validated G&#x003b1;i2 or G&#x003b2;2 shRNA <xref ref-type="bibr" rid="pone.0004559-Hwang1">&#x0005b;5&#x0005d;</xref>, <xref ref-type="bibr" rid="pone.0004559-Hwang2">&#x0005b;6&#x0005d;</xref>. The target gene silencing activity of each shRNA in RAW264.7 cells was assessed by QRT-PCR and immunoblotting for endogenous proteins. Consistent with the QRT-PCR data, significant decreases in the levels of G&#x003b1;i2 or G&#x003b2;2 proteins were observed in the shRNA expressing cells (<xref ref-type="fig" rid="pone-0004559-g001">Figure 1</xref>).</p></sec><sec id="s2c"><title>siRNA, ASO and shRNA as RNAi tools</title><p>It was confirmed by DNA microarray analysis using custom-made inkjet-printed 16K oligonucleotide chips (Gene Expression Omnibus platform accession number GPL254: <ext-link ext-link-type="uri" xlink:href="http://www.ncbi.nlm.nih.gov/projects/geo/">http://www.ncbi.nlm.nih.gov/projects/geo/</ext-link>) that the transfection of siRNA against G&#x003b1;i2 or G&#x003b2;2 showed significant levels of the target gene knockdown (<xref ref-type="fig" rid="pone-0004559-g002">Figure 2</xref>). Cells were harvested at 48 hr post-transfection for assessment of mRNA, and gene expression was assessed using a DNA microarray and by QRT-PCR. Control samples were mock-treated with transfection reagent to determine the baseline levels of gene expression. It was found that 400 nM siRNA is invariably more effective than 100 nM or 200 nM. Although several papers have noted that siRNA reaches maximal effectiveness at a concentration lower than 100 nM <xref ref-type="bibr" rid="pone.0004559-Kim1">&#x0005b;29&#x0005d;</xref>, <xref ref-type="bibr" rid="pone.0004559-Overhoff1">&#x0005b;30&#x0005d;</xref>, Song et al. <xref ref-type="bibr" rid="pone.0004559-Song1">&#x0005b;31&#x0005d;</xref> reported that primary macrophages required 1 &#x000b5;M siRNA to achieve a maximal effect. For any given siRNA, a comparable level of knockdown can be achieved with at least a 10-fold lower siRNA concentration using NIH3T3 cells (data not shown). The present results suggest that the requirement for a high siRNA concentration in RAW264.7 cells is simply a function of their low transfection efficiency.</p><fig id="pone-0004559-g002" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0004559.g002</object-id><label>Figure 2</label><caption><title>Hierarchically clustered dendrograms of gene expression changes.</title><p>Clustering was achieved using the CLUSTER and TREEVIEW programs (<ext-link ext-link-type="uri" xlink:href="http://rana.lbl.gov/EisenSoftware.htm">http://rana.lbl.gov/EisenSoftware.htm</ext-link>). Each row represents a gene, and each column represents a particular sample. (A) G&#x003b1;i2 gene knockdown (LV40 and LV11: shRNA- expressing lentivirus transfected cell lines; I and L: I or L form of siRNA transfected into cells). (B) G&#x003b2;2 gene knockdown (LV4 and LV43: shRNA-expressing lentivirus transfected cell lines; G and H: G or H form of siRNA transfected into cells; Gb2-ASO: antisense oligonucleotide). The expression level relative to that of the control cells is provided by colors shown in log<sub>2</sub> scale. The target genes, G&#x003b1;i2 and G&#x003b2;2, are highlighted by arrows. The apparent down-regulation of IL13ra2 in the G&#x003b1;i2-deficient cells and IL1rn in the G&#x003b2;2-deficient cells are also highlighted (see context).</p></caption><graphic xlink:href="pone.0004559.g002"/></fig><p>Validated ASOs against the G&#x003b1;i2 or G&#x003b2;2 gene were obtained from ISIS Pharmaceuticals, Inc. (Carlsbad, CA). The ASOs used were phosphorothioate oligodeoxynucleotides with 2&#x02032;-O-methoxyethyl incorporated to enhance their affinity for RNA sequences and their resistance to degradation by nucleases. RAW 264.7 cells were transfected with 400 nM of ASO and were harvested for mRNA analysis at 48 hr post-transfection. Results from the DNA microarrays showed a detectable knockdown for ASO against G&#x003b2;2 message (<xref ref-type="fig" rid="pone-0004559-g002">Figure 2B</xref>) as well as a specific knockdown for ASO targeting G&#x003b1;i2. Another set of G&#x003b1;i2 ASO data was not included in the analysis shown in <xref ref-type="fig" rid="pone-0004559-g002">Figure 2A</xref> due to the unexpected induction of TLR-related genes. This will be discussed later.</p><p>It has been shown that the knockdown effect mediated by siRNA or ASO is sustained for up to several days <xref ref-type="bibr" rid="pone.0004559-Kim1">&#x0005b;29&#x0005d;</xref>, <xref ref-type="bibr" rid="pone.0004559-Endesfelder1">&#x0005b;32&#x0005d;</xref>, <xref ref-type="bibr" rid="pone.0004559-Yin1">&#x0005b;33&#x0005d;</xref>. However, creation of a cell line infected with a shRNA-expressing lentivirus provides an approach for gene knockdown over a longer term. The analysis in <xref ref-type="fig" rid="pone-0004559-g002">Figure 2</xref> shows that lentiviral vector-based RNAi works well in RAW 264.7 cells with a robust knockdown of the G&#x003b1;i2 and G&#x003b2;2 target genes.</p></sec><sec id="s2d"><title>Induction of TLR-related genes by ASO designed for a knockdown of G&#x003b1;i2</title><p>The ASO tests showed an unexpected observation of a significant degree of induction of TLR-related genes by one of ASOs designed for the knockdown of the G&#x003b1;i2 gene. Kim et al. <xref ref-type="bibr" rid="pone.0004559-Kim2">&#x0005b;34&#x0005d;</xref> found a very potent induction of interferon &#x003b1; and &#x003b2; by short single-stranded RNAs (ssRNAs) transcribed with T3, T7 and Sp6 RNA polymerases. In their studies, analyses of the potential mediators of this response revealed that the initiating 5&#x02032; triphosphate is required for interferon induction. Moreover, single-strand RNA bearing 5&#x02032; phosphate could activate RIG-1 mediated anti-viral responses <xref ref-type="bibr" rid="pone.0004559-Pichlmair1">&#x0005b;35&#x0005d;</xref> and it was also shown that 5&#x02032; triphosphate is the ligand for RIG-1 <xref ref-type="bibr" rid="pone.0004559-Hornung1">&#x0005b;36&#x0005d;</xref>. However, with the present ASO, neither RNA polymerase nor 5&#x02032; triphosphate was used. Nonetheless, a transcription profiling analysis revealed patterns of regulation that were very similar to the patterns of expression induced by ligands that trigger TLRs and clustered with them (<xref ref-type="fig" rid="pone-0004559-g003">Figure 3</xref>), showing a higher expression of IL1&#x003b2;, IFN&#x003b1;-inducible protein, chemokine (C-C motif) ligand 2 (Ccl2), IFN-induced protein with tetratricopeptide repeats 1 (Ifit1), 2 (Ifit2) and 3 (Ifit3), granulocyte colony stimulating factor 3 (Csf3), immunoresponsive gene 1 (Irg1), IL6, guanylate nucleotide binding protein 1 (Gbp1), 2 (Gbp2) and 4 (Gbp4), dual specificity phosphatase 1 (Dusp1) and 2 (Dusp2), IL10, and growth arrest and DNA-damage-inducible 45&#x003b1; (Gadd45&#x003b1;) (not all data shown: separate paper in preparation). When the ASO sequence for G&#x003b1;i2 was studied further, it was found that the G&#x003b1;i2 antisense oligonucleotide sequence has several CpG motifs (<named-content content-type="gene">5&#x02032;-TTT AGA G<bold>CG</bold> CT<bold>C G</bold>GC TGC <bold>CG</bold>-3&#x02032;: multiple unmethylated <bold>CpG</bold> appeared and one purine-purine-<bold>CpG</bold>-pyrimidine-pyrimidine existed). Unmethylated CpG motifs are present in bacterial genomic DNA and function as a pattern recognition motif by the host innate immune system <xref ref-type="bibr" rid="pone.0004559-Krieg1">&#x0005b;37&#x0005d;</xref>, <xref ref-type="bibr" rid="pone.0004559-Yi1">&#x0005b;38&#x0005d;</xref>. For mouse, the sequence GA<bold>CG</bold>TT appears to be optimal, but flanking nucleotides to the central CpG core appear to influence recognition to some degree. Oligonucleotides containing the core CpG motif might bind to the TLR9 whose expression was confirmed in RAW 264.7 cells (<xref ref-type="table" rid="pone-0004559-t002">Table 2</xref>). TLR9 engagement triggers alteration of the cellular redox balance, tyrosine phosphorylation of vav1 by a src-related tyrosine kinase <xref ref-type="bibr" rid="pone.0004559-Stovall1">&#x0005b;39&#x0005d;</xref>, and the induction of cell signaling pathways including mitogen-activated protein kinases (MAPKs) and NF&#x003ba;B <xref ref-type="bibr" rid="pone.0004559-Krieg1">&#x0005b;37&#x0005d;</xref>. Interleukin-1 receptor-associated kinase (IRAK) and/or tumor-necrosis-factor-receptor-associated factor 6 (TRAF6) may be diverging points for NF&#x003ba;B activation in response to CpG DNA in RAW264.7 cells <xref ref-type="bibr" rid="pone.0004559-Yeo1">&#x0005b;40&#x0005d;</xref>, <xref ref-type="bibr" rid="pone.0004559-Yeo2">&#x0005b;41&#x0005d;</xref>. In our ASO sequence against G&#x003b1;i2, three copies of the unmethylated CpG motif per oligonucleotide led to the enhanced activation of TLRs.</named-content></p><fig id="pone-0004559-g003" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0004559.g003</object-id><label>Figure 3</label><caption><title>Hierarchical clustering of gene expression for different RNAi platforms or ligand treatments in G&#x003b1;i2 knockdown RAW 264.7 cells.</title><p>While Pam<sub>2</sub> 0.5 h (1st) and Pam<sub>2</sub> 0.5 h (2nd) were tested in lentivirus vector transfected RAW cell lines, Pam<sub>2</sub> 0.5 h was carried out in wild type RAW 264.7 cells together with other TLR ligand experiments, in this case Pam<sub>3</sub> , Zymosan, Taxol, PolyIC and CpG.</p></caption><graphic xlink:href="pone.0004559.g003"/></fig><table-wrap id="pone-0004559-t002" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0004559.t002</object-id><label>Table 2</label><caption><title>RT-PCR confirmation of TLR expression in RAW 264.7 cells (P: present, A: absent).</title></caption><graphic id="pone-0004559-t002-2" xlink:href="pone.0004559.t002"/><table frame="hsides" rules="groups" alternate-form-of="pone-0004559-t002-2"><colgroup span="1"><col align="left" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/></colgroup><thead><tr><td align="left" rowspan="1" colspan="1">Gene Name</td><td align="left" rowspan="1" colspan="1">RT-PCR Results in RAW</td><td align="left" rowspan="1" colspan="1">Abundance</td><td align="left" rowspan="1" colspan="1">Affymetrix Chip Call</td></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">TLR1</td><td align="left" rowspan="1" colspan="1">P</td><td align="left" rowspan="1" colspan="1">High</td><td align="left" rowspan="1" colspan="1">P</td></tr><tr><td align="left" rowspan="1" colspan="1">TLR2</td><td align="left" rowspan="1" colspan="1">P</td><td align="left" rowspan="1" colspan="1">High</td><td align="left" rowspan="1" colspan="1">P</td></tr><tr><td align="left" rowspan="1" colspan="1">TLR3</td><td align="left" rowspan="1" colspan="1">P</td><td align="left" rowspan="1" colspan="1">High</td><td align="left" rowspan="1" colspan="1">P</td></tr><tr><td align="left" rowspan="1" colspan="1">TLR4</td><td align="left" rowspan="1" colspan="1">P</td><td align="left" rowspan="1" colspan="1">Low</td><td align="left" rowspan="1" colspan="1">P</td></tr><tr><td align="left" rowspan="1" colspan="1">TLR5</td><td align="left" rowspan="1" colspan="1">A</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">A</td></tr><tr><td align="left" rowspan="1" colspan="1">TLR6</td><td align="left" rowspan="1" colspan="1">P</td><td align="left" rowspan="1" colspan="1">Medium</td><td align="left" rowspan="1" colspan="1">P</td></tr><tr><td align="left" rowspan="1" colspan="1">TLR7</td><td align="left" rowspan="1" colspan="1">P</td><td align="left" rowspan="1" colspan="1">High</td><td align="left" rowspan="1" colspan="1">P</td></tr><tr><td align="left" rowspan="1" colspan="1">TLR8</td><td align="left" rowspan="1" colspan="1">A</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">A</td></tr><tr><td align="left" rowspan="1" colspan="1">TLR9</td><td align="left" rowspan="1" colspan="1">P</td><td align="left" rowspan="1" colspan="1">High</td><td align="left" rowspan="1" colspan="1">A</td></tr><tr><td align="left" rowspan="1" colspan="1">TLR10 (not in mouse)</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">TLR11</td><td align="left" rowspan="1" colspan="1">A</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">TLR12</td><td align="left" rowspan="1" colspan="1">P</td><td align="left" rowspan="1" colspan="1">Medium</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">TLR13</td><td align="left" rowspan="1" colspan="1">P</td><td align="left" rowspan="1" colspan="1">High</td><td align="left" rowspan="1" colspan="1"/></tr></tbody></table></table-wrap></sec><sec id="s2e"><title>The effects of G&#x003b1;i2 or G&#x003b2;2 knockdown</title><p>Gene expression analyses were performed for all of the transduced cells using custom-made 16K oligonucleotide DNA microarrays. It is well known that the individual members of the G protein heterotrimers are necessary for the stability of their binding partners <xref ref-type="bibr" rid="pone.0004559-Hwang1">&#x0005b;5&#x0005d;</xref>, <xref ref-type="bibr" rid="pone.0004559-Wang1">&#x0005b;42&#x0005d;</xref>. While the regulated number of genes in each knockdown experiment in which a two-fold cut-off was used was between about 30 to 80, changes in the mRNA expression levels of other &#x003b1;, &#x003b2; or &#x003b3; G proteins were not detected in siRNA- or ASO-treated cells or in shRNA-containing cells (<xref ref-type="supplementary-material" rid="pone.0004559.s002">Table S2</xref>), indicating that the absence of the G&#x003b1;i2 or G&#x003b2;2 subunit protein did not affect the levels of transcripts encoding other individual members of the G protein heterotrimers.</p><p>In addition to the knockdown of the intended target, apparent regulation of other genes depending on the RNAi platforms was found (<xref ref-type="fig" rid="pone-0004559-g002">Figure 2</xref>). As shown in <xref ref-type="fig" rid="pone-0004559-g002">Figure 2</xref>, there appeared to be up- or down-regulations of some genes in both G&#x003b1;i2- and G&#x003b2;2-deficient cell lines. The apparent down-regulation of interleukin 13 receptor alpha2 (IL13ra2) in the G&#x003b1;i2-deficient cells and interleukin 1 receptor antagonist (IL1rn) in the G&#x003b2;2-deficient cells may be noteworthy, as these changes were observed with all platforms (<xref ref-type="fig" rid="pone-0004559-g002">Figure 2</xref>). This result is intriguing given the fact that these proteins are not reported as being capable of coupling to either G&#x003b1;i2 or G&#x003b2;2. A biological link was not found for G&#x003b1;i2 or G&#x003b2;2 to IL13ra2 or IL1rn in published reports; however, it was noted that the selected oligonucleotide sequences used for G&#x003b1;i2 or G&#x003b2;2 RNAi tests had homology of 7 to 8 contiguous nucleotides to either IL13ra2 (siRNA structure I) or IL1rn (siRNA structure G and ASO) (<xref ref-type="fig" rid="pone-0004559-g004">Figures 4A and B</xref>). While the direct silencing of nontargeted genes containing as few as eleven contiguous nucleotides of identity to the siRNA has been reported <xref ref-type="bibr" rid="pone.0004559-Jackson1">&#x0005b;43&#x0005d;</xref>, it appears to be unlikely that 7 to 8 contiguous nucleotides of identity can regulate the expression of unintended targets. Furthermore, given the fact that not all of the siRNA, shRNA or ASO sequences showed significant homology to the IL13ra2 or IL1rn sequences (<xref ref-type="fig" rid="pone-0004559-g004">Figure 4</xref>), these common down-regulations may be due to an unappreciated biological consequence of G&#x003b1;i2 or G&#x003b2;2 depletion and shed light onto the unidentified functions of these G-protein subunits. Interestingly, the expression of RGS16 (Regulators of G protein Signaling 16) was also downregulated in many of the tests for either G&#x003b1;i2 or G&#x003b2;2 (<xref ref-type="fig" rid="pone-0004559-g002">Figure 2</xref>). While RGS17 has been reported to act as a GTPase-activating protein (GAP) on free G&#x003b1;i2 and G&#x003b1;o under pre-steady-state conditions <xref ref-type="bibr" rid="pone.0004559-Mao1">&#x0005b;44&#x0005d;</xref>, it remains to be determined if the depletion of RGS16 in the G&#x003b1;i2 and G&#x003b2;2 knockdown cells is biologically relevant.</p><fig id="pone-0004559-g004" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0004559.g004</object-id><label>Figure 4</label><caption><title>Sequence homologies of the oligonucleotides used in siRNA, shRNA or ASO for (A) G&#x003b1;i2 or (B) G&#x003b2;2.</title><p>Sequences were analyzed by OMIGA 2.0 (Rainbow Technologies, Inc.).</p></caption><graphic xlink:href="pone.0004559.g004"/></fig></sec><sec id="s2f"><title>RNAi-based perturbations</title><p>The present studies were extended to reveal which signaling networks are associated with the reduction of the G&#x003b1;i2 protein in the presence of lipopolysaccharide (LPS), Pam2CSK4 (Pam<sub>2</sub>) or prostaglandin E2 (PGE<sub>2</sub>). To observe the effect of the absence of G&#x003b1;i2 in a ligand-dependent manner, gene expression was examined in both control RAW 264.7 cells (control lentiviral vector transfected cell lines) and G&#x003b1;i2-deficient cells (G&#x003b1;i2 shRNA-harboring lentiviral cell lines) after stimulation with LPS (100 ng/ml LPS and 100 pM LPS-binding peptide), Pam<sub>2</sub> (350 nM) or PGE<sub>2</sub> (10 &#x000b5;M) using 16K oligonucleotide microarrays. According to the criterion of a &#x02265;2 fold change in expression, exposure of the cells to LPS for 30 min resulted in the up-regulation of nearly 100 transcripts in both control and G&#x003b1;i2 knockdown cells in a similar pattern. A partial image of the set of clustered dendrograms is shown in <xref ref-type="fig" rid="pone-0004559-g003">Figure 3</xref>. Pam<sub>2</sub> or PGE<sub>2</sub> treatment of both cells also led to a very similar pattern of gene expression. However, there were some subtle differences in the changes in transcript levels induced by LPS or Pam<sub>2</sub> treatment in the cells lacking the G&#x003b1;i2 protein (<xref ref-type="table" rid="pone-0004559-t003">Table 3</xref>). These genes include early growth response 2 (Egr2), the nuclear factor of kappa light polypeptide gene enhancer in B-cells inhibitor, zeta (Nfkbiz), tumor necrosis factor (TNF) and the 1810011O10 RIKEN clone, whose expressions were enhanced by LPS or Pam<sub>2</sub> in G&#x003b1;i2-deficient cells.</p><table-wrap id="pone-0004559-t003" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0004559.t003</object-id><label>Table 3</label><caption><title>Ligand-induced gene expression changes in G&#x003b1;i2-deficient cells.</title></caption><graphic id="pone-0004559-t003-3" xlink:href="pone.0004559.t003"/><table frame="hsides" rules="groups" alternate-form-of="pone-0004559-t003-3"><colgroup span="1"><col align="left" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/></colgroup><thead><tr><td align="left" rowspan="1" colspan="1">Gene</td><td align="left" rowspan="1" colspan="1">Assay</td><td align="left" rowspan="1" colspan="1">W vs Gi2-sh</td><td align="left" rowspan="1" colspan="1">LPS 0.5 h</td><td align="left" rowspan="1" colspan="1">Gi2: LPS 0.5 h</td><td align="left" rowspan="1" colspan="1">F: LPS</td><td align="left" rowspan="1" colspan="1">Pam2 0.5 h</td><td align="left" rowspan="1" colspan="1">Gi2: Pam2 0.5 h</td><td align="left" rowspan="1" colspan="1">F: Pam2</td><td align="left" rowspan="1" colspan="1">PGE 0.5 h</td><td align="left" rowspan="1" colspan="1">Gi2: PGE 0.5 h</td><td align="left" rowspan="1" colspan="1">F: PGE</td></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">Nfkbiz</td><td align="left" rowspan="1" colspan="1">Microarray</td><td align="left" rowspan="1" colspan="1">1.03</td><td align="left" rowspan="1" colspan="1">24.94</td><td align="left" rowspan="1" colspan="1">30.70</td><td align="left" rowspan="1" colspan="1"><bold>5.76</bold></td><td align="left" rowspan="1" colspan="1">27.80</td><td align="left" rowspan="1" colspan="1">30.05</td><td align="left" rowspan="1" colspan="1"><bold>2.25</bold></td><td align="left" rowspan="1" colspan="1">1.41</td><td align="left" rowspan="1" colspan="1">1.34</td><td align="left" rowspan="1" colspan="1">&#x02212;0.07</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">QRT-PCR</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">72.78</td><td align="left" rowspan="1" colspan="1">123.26</td><td align="left" rowspan="1" colspan="1"><bold>50.48</bold></td><td align="left" rowspan="1" colspan="1">86.74</td><td align="left" rowspan="1" colspan="1">131.52</td><td align="left" rowspan="1" colspan="1"><bold>44.79</bold></td><td align="left" rowspan="1" colspan="1">1.48</td><td align="left" rowspan="1" colspan="1">1.34</td><td align="left" rowspan="1" colspan="1">&#x02212;0.14</td></tr><tr><td align="left" rowspan="1" colspan="1">Egr2</td><td align="left" rowspan="1" colspan="1">Microarray</td><td align="left" rowspan="1" colspan="1">0.60</td><td align="left" rowspan="1" colspan="1">12.11</td><td align="left" rowspan="1" colspan="1">18.10</td><td align="left" rowspan="1" colspan="1"><bold>5.99</bold></td><td align="left" rowspan="1" colspan="1">14.80</td><td align="left" rowspan="1" colspan="1">20.74</td><td align="left" rowspan="1" colspan="1"><bold>5.94</bold></td><td align="left" rowspan="1" colspan="1">0.71</td><td align="left" rowspan="1" colspan="1">0.78</td><td align="left" rowspan="1" colspan="1">0.14</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">QRT-PCR</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">21.17</td><td align="left" rowspan="1" colspan="1">25.23</td><td align="left" rowspan="1" colspan="1"><bold>4.06</bold></td><td align="left" rowspan="1" colspan="1">16.86</td><td align="left" rowspan="1" colspan="1">45.33</td><td align="left" rowspan="1" colspan="1"><bold>28.47</bold></td><td align="left" rowspan="1" colspan="1">0.76</td><td align="left" rowspan="1" colspan="1">0.52</td><td align="left" rowspan="1" colspan="1">&#x02212;0.62</td></tr><tr><td align="left" rowspan="1" colspan="1">1810011O10Rik</td><td align="left" rowspan="1" colspan="1">Microarray</td><td align="left" rowspan="1" colspan="1">1.01</td><td align="left" rowspan="1" colspan="1">4.81</td><td align="left" rowspan="1" colspan="1">10.16</td><td align="left" rowspan="1" colspan="1"><bold>5.35</bold></td><td align="left" rowspan="1" colspan="1">4.00</td><td align="left" rowspan="1" colspan="1">8.63</td><td align="left" rowspan="1" colspan="1"><bold>4.63</bold></td><td align="left" rowspan="1" colspan="1">1.42</td><td align="left" rowspan="1" colspan="1">1.34</td><td align="left" rowspan="1" colspan="1">&#x02212;0.09</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">QRT-PCR</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">53.51</td><td align="left" rowspan="1" colspan="1">84.18</td><td align="left" rowspan="1" colspan="1"><bold>30.67</bold></td><td align="left" rowspan="1" colspan="1">71.06</td><td align="left" rowspan="1" colspan="1">116.53</td><td align="left" rowspan="1" colspan="1"><bold>45.47</bold></td><td align="left" rowspan="1" colspan="1">3.45</td><td align="left" rowspan="1" colspan="1">2.32</td><td align="left" rowspan="1" colspan="1">&#x02212;1.13</td></tr><tr><td align="left" rowspan="1" colspan="1">Tnf</td><td align="left" rowspan="1" colspan="1">Microarray</td><td align="left" rowspan="1" colspan="1">0.92</td><td align="left" rowspan="1" colspan="1">7.99</td><td align="left" rowspan="1" colspan="1">13.17</td><td align="left" rowspan="1" colspan="1"><bold>5.18</bold></td><td align="left" rowspan="1" colspan="1">7.93</td><td align="left" rowspan="1" colspan="1">18.22</td><td align="left" rowspan="1" colspan="1"><bold>10.29</bold></td><td align="left" rowspan="1" colspan="1">0.69</td><td align="left" rowspan="1" colspan="1">0.66</td><td align="left" rowspan="1" colspan="1">&#x02212;0.06</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">QRT-PCR</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">15.44</td><td align="left" rowspan="1" colspan="1">23.70</td><td align="left" rowspan="1" colspan="1"><bold>8.26</bold></td><td align="left" rowspan="1" colspan="1">15.86</td><td align="left" rowspan="1" colspan="1">20.93</td><td align="left" rowspan="1" colspan="1"><bold>5.07</bold></td><td align="left" rowspan="1" colspan="1">0.92</td><td align="left" rowspan="1" colspan="1">0.55</td><td align="left" rowspan="1" colspan="1">&#x02212;0.73</td></tr></tbody></table><table-wrap-foot><fn id="nt102"><label/><p>Note: The numbers are in fold differences. F (F factor) was calculated by (ligand effect in knockdown) &#x02013; (ligand effect in wild type): Ligand effect&#x0200a;&#x0003d;&#x0200a;2<sup>X</sup>&#x02212;1, if X&#x02265;0 or &#x0200a;&#x0003d;&#x0200a;1&#x02212;1/2<sup>X</sup>, if X&#x0003c;0.</p></fn><fn id="nt103"><label/><p>Where, X is the log<sub>2</sub> ratio.</p></fn></table-wrap-foot></table-wrap><p>LPS is the major constituent of the outer membrane of Gram-negative bacteria. LPS binds to the cell surface receptor CD14, which enhances TLR4-dependent LPS recognition <xref ref-type="bibr" rid="pone.0004559-Akira1">&#x0005b;45&#x0005d;</xref>, <xref ref-type="bibr" rid="pone.0004559-Yamamoto1">&#x0005b;46&#x0005d;</xref>, <xref ref-type="bibr" rid="pone.0004559-Krishnan1">&#x0005b;47&#x0005d;</xref>. TLR4 activation engages a set of MyD88 (myeloid differentiation primary-response protein 88) adaptor family members, including MyD88, TIRAP (TIR domain containing adaptor protein), TRIF (TIR domain containing adaptor protein inducing IFN&#x003b2;), and TRAM (TRIF related adaptor molecule). Pam<sub>2</sub> is a synthetic diacylated lipopeptide, and these lipid-modified proteins are present in the cell membranes of bacterial cell walls. The intracytoplasmic signaling events associated with Pam<sub>2</sub> stimulation are mainly engaged in TLR2/6 activation, which also leads to stimulation of the MyD88-dependent pathway <xref ref-type="bibr" rid="pone.0004559-Takeda1">&#x0005b;48&#x0005d;</xref>. Therefore, the synergistic effects of G&#x003b1;i2 knockdown on LPS&#x02013; or Pam<sub>2</sub>&#x02013;induced Egr2, Nfkbiz or TNF (as shown in <xref ref-type="table" rid="pone-0004559-t003">Table 3</xref>) suggest that some aspect of these signaling pathways is influenced by G&#x003b1;i2 levels. This may reflect a heightened response or defective negative regulation in G&#x003b1;i2-deficient cells. Consistent with the present results, stimulation of G&#x003b1;i2-deficient peripheral T cells induced a hyper-responsive profile of interleukin-2, tumor necrosis factor, and interferon-gamma production <xref ref-type="bibr" rid="pone.0004559-Rudolph1">&#x0005b;18&#x0005d;</xref>. Unlike G&#x003b1;i1 or G&#x003b1;i3, cells deficient in G&#x003b1;i2 were reported to be hyper-responsive to cytokines, including IFN-gamma and IL-4 production following activation <xref ref-type="bibr" rid="pone.0004559-Huang1">&#x0005b;20&#x0005d;</xref>.</p></sec></sec><sec id="s3"><title>Discussion</title><p>It is well established that siRNA efficacy is determined by how effectively the siRNA is incorporated into RISC <xref ref-type="bibr" rid="pone.0004559-Castanotto1">&#x0005b;49&#x0005d;</xref>, <xref ref-type="bibr" rid="pone.0004559-Tafer1">&#x0005b;50&#x0005d;</xref>, <xref ref-type="bibr" rid="pone.0004559-Koller1">&#x0005b;51&#x0005d;</xref>. This necessitates the testing of several candidate siRNAs to identify an effective reagent. Recently, it has been shown that testing of many siRNAs can be circumvented by <italic>in vitro</italic> digestion of a long dsRNA using the dicer enzyme. This produces a population of siRNAs covering a much larger region of target sequence and usually obviates the need to test multiple sequences for each gene. The caveats, however, are that this approach theoretically increases the possibility of an undesirable knockdown of other genes with significant homology to the target sequences used as the dicer template, and siRNAs derived from synthesized long dsRNAs by the T7 RNA polymerase system can trigger a potent induction of interferon &#x003b1; and &#x003b2; in a variety of cell lines due to the initiating 5&#x02032; triphosphate <xref ref-type="bibr" rid="pone.0004559-Kim2">&#x0005b;34&#x0005d;</xref>.</p><p>Three different silencing/delivery systems (siRNA, ASO and shRNA) and different sequences in the target genes in each case were used to assess how the knockdown of a particular gene may affect molecular mechanisms. The significant knockdown in the G&#x003b1;i2 and G&#x003b2;2 protein levels suggests that the knockdown levels achievable with siRNA, ASO or shRNA may be sufficient to assess a transient or permanent phenotype <xref ref-type="bibr" rid="pone.0004559-Kim1">&#x0005b;29&#x0005d;</xref>.</p><p>&#x02018;Off-target effects&#x02019; can occur if the sequence identity between the siRNA and random mRNA transcripts is high enough to cause RNAi to knockdown the expression of non-targeted genes. However, in our experiments, sequence-specific off-target effects were not obvious except for the ASO designed for G&#x003b1;i2, which indicates that the design of oligonucleotides is certainly important and should be tested in the genomic scale before it is used to knockdown a target gene in biological studies. Kim et al. <xref ref-type="bibr" rid="pone.0004559-Kim1">&#x0005b;29&#x0005d;</xref> and Siolas et al. <xref ref-type="bibr" rid="pone.0004559-Siolas1">&#x0005b;52&#x0005d;</xref> found that synthetic RNA duplexes &#x0223c;27 nucleotides in length can be up to 100 times more potent than traditional 21-unit siRNA oligomers. Enhancing the potency of RNAi duplexes and thus lowering the effective concentration of that molecule is another preferable working direction to minimize off-target effects. The enhanced potency of the &#x0223c;27 nucleotide siRNA is attributed to the fact that it is diced by the dicer and directly delivered to the RNA-induced silencing complex (RISC).</p><p>Extracellular stimulants induce various cellular responses by regulating diverse pathways, and perturbation of any genes in the pathway can generate altered regulation of signaling networks. In a mouse model, <italic>in vitro</italic> stimulation of splenocytes with formalin-killed <italic>Staphylococcus aureus</italic> resulted in significantly increased production of IL1&#x003b2;, TNF, and IL12p40 in G&#x003b1;i2 (&#x02212;/&#x02212;) compared to control mice <xref ref-type="bibr" rid="pone.0004559-Bjursten2">&#x0005b;26&#x0005d;</xref>. Mice with targeted deletion of G&#x003b1;i2 develop an inflammatory bowel disease closely resembling ulcerative colitis, and the IFN&#x003b3; and IL1&#x003b2; levels were increased in the inflamed colons <xref ref-type="bibr" rid="pone.0004559-Hornquist1">&#x0005b;53&#x0005d;</xref>. In RAW 264.7 cells, the expression level of G&#x003b1;i2 was relatively high compared to that of G&#x003b1;i3, whereas G&#x003b1;i1 was not expressed (<xref ref-type="table" rid="pone-0004559-t001">Table 1</xref>). G&#x003b1;i2 proteins may play a role in modulating LPS-activated signaling through TLR4, leading to inflammatory mediator production in RAW 264.7 cells. There was a significant increase in the LPS-induced production of TNF&#x003b1; in G&#x003b1;i2-deficient RAW 264.7 cells compared with control cells (<xref ref-type="table" rid="pone-0004559-t003">Table 3</xref>). Subsequent QRT-PCR studies also confirmed that TNF&#x003b1; levels following a LPS challenge were significantly greater in G&#x003b1;i2-deficient cells. This is consistent with the published data from G&#x003b1;i2 (&#x02212;/&#x02212;) mice <xref ref-type="bibr" rid="pone.0004559-Bjursten2">&#x0005b;26&#x0005d;</xref>, <xref ref-type="bibr" rid="pone.0004559-Fan1">&#x0005b;54&#x0005d;</xref>.</p><p>Taken together, success was obtained with the knockdown of target genes in RAW 264.7 cells using chemically synthesized siRNA, lentiviral shRNA and ASO. The specificity of the different platforms of RNAi was also assessed through DNA microarrays, and the findings showed the successful development of siRNA reagents against the genes of interest and the useful application of vector-based RNAi to RAW 264.7 cells for functional studies. Well-designed RNAi would be a very useful tool to knockdown specific target genes and to study the functional roles of molecules within the relevant signaling network system.</p></sec><sec sec-type="materials|methods" id="s4"><title>Materials and Methods</title><sec id="s4a"><title>Nucleic acid sequences for shRNAs, siRNAs and ASOs</title><p>The shRNAs, siRNAs and ASOs used in these studies were based on the following sequences: shRNAs (G&#x003b1;i2-LV40: <named-content content-type="gene">5&#x02032;-GTC TAC AGC AAC ACC ATC C-3&#x02032;</named-content>, G&#x003b1;i2-LV11: <named-content content-type="gene">5&#x02032;-GCA CAG AGT GAC TAC ATC C-3&#x02032;</named-content>, G&#x003b2;2-LV43 &#x00026; 4: <named-content content-type="gene">5&#x02032;-CAT CTG CTC CAT CTA TAG TC-3&#x02032;</named-content>), siRNAs (G&#x003b1;i2-I: <named-content content-type="gene">5&#x02032;-GAG CAA GTT TGA GGA TCT A-3&#x02032;</named-content>, G&#x003b1;i2-L: <named-content content-type="gene">5&#x02032;-CCG CTT ACT ACC TGA ATG A-3&#x02032;</named-content>, G&#x003b2;2-G: <named-content content-type="gene">5&#x02032;-GGA CGG AAA GCT CAT CAT T-3&#x02032;</named-content>, G&#x003b2;2-H: <named-content content-type="gene">5&#x02032;-GGA CGA CAA CCA AAT CAT C-3&#x02032;</named-content>) and ASOs (G&#x003b1;i2: <named-content content-type="gene">5&#x02032;-TTT AGA GCG CTC GGC TGC CG-3&#x02032;</named-content>, G&#x003b2;2: <named-content content-type="gene">5&#x02032;-ATG AGC TTT CCG TCC TGG GA-3&#x02032;</named-content>).</p></sec><sec id="s4b"><title>siRNAs or ASO treatments</title><p>All ASOs in this study were synthesized by ISIS Pharmaceuticals, and all siRNAs were synthesized and HPLC-purified by Qiagen Inc. (Valencia, CA). Briefly, RAW 264.7 cells in 24-well dishes were transfected with 400 nM of either ASO or siRNA using either FuGENE6 (Roche Molecular Biochemicals, Indianapolis, IN) or Lipofectamine 2000 (Invitrogen, Carlsbad, CA), respectively. For siRNA transfection, an incubation volume of 200 &#x000b5;l was used for 4 hr followed by the addition of media up to 1 ml. For ASO transfection, an incubation volume of 500 &#x000b5;l was used. siRNA transfections were repeated 24 hr after the initial transfection while a single transfection was done for ASO treatments. Cells were harvested at 48 hr post-transfection for isolation of the RNA or at 72 hr post-transfection for isolation of the protein.</p></sec><sec id="s4c"><title>Virus construction</title><p>Lentiviral vectors were constructed and used for virus generation as described previously <xref ref-type="bibr" rid="pone.0004559-Hwang1">&#x0005b;5&#x0005d;</xref>, <xref ref-type="bibr" rid="pone.0004559-Hwang2">&#x0005b;6&#x0005d;</xref>. Annealed shRNA linkers were ligated into a <italic>Bam</italic>H1/<italic>Xho</italic>1-digested pEN_mH1c plasmid. The cassette containing the mH1 promoter and the shRNA was subcloned to a lentiviral expression vector by site-specific recombination using the Gateway system (Invitrogen). The lentiviral vector contains the GFP gene driven by the ubiquitin promoter followed by an IRES (internal ribosome entry site) sequence and an antibiotic resistance gene for the selection of infected cells. The resultant lentiviral vectors were transfected into 293T cells two other plasmids referred to as &#x02018;packaging&#x02019; and &#x02018;envelope&#x02019; plasmids: pCMV&#x00394;R8.91 (expresses HIV <italic>gag</italic>, <italic>pol</italic> and <italic>rev</italic> genes), and pMD.G (expresses vesicular stomatitis virus G envelope protein), respectively. The packaging and envelope plasmids were a gift from the Didier Trono Lab, Geneva, Switzerland <xref ref-type="bibr" rid="pone.0004559-Salmon1">&#x0005b;55&#x0005d;</xref>. At 48 hr post-transfection, culture supernatants were collected and concentrated using Centricon Plus-80 units according to the manufacturer's instructions (Millipore Corporate, Billerica, MA). Virus was titrated by infecting 293T cells and assessing the percent of GFP positive cells using cytometric analysis 48 hr post-infection. The titered virus was used to infect RAW 264.7 cells at a MOI (multiplicity of infection) of five 293T-transducing units per RAW 264.7 cell, at virus concentrations of 1 to 5&#x000d7;10<sup>7</sup>/ml. These infection conditions routinely resulted in an average of 20&#x00025; transduction efficiency, suggesting that a single productive viral integration occurs for every 25 viruses used on RAW 264.7 cells. Infected cells were selected according to their antibiotic resistance. These infection conditions routinely resulted in 10&#x02013;25&#x00025; transduction efficiency, suggesting that approximately one productive viral integration occurs for every 5 viruses used on RAW 264.7 cells. Infected cells were selected according to their antibiotic resistance.</p></sec><sec id="s4d"><title>Western blotting</title><p>Cells were lysed with lysis buffer containing 150 mM NaCl, 50 mM NaF, 20 mM Tris, pH 7.5, 1&#x00025; Triton X-100, 0.5&#x00025; sodium deoxycholate, 0.1&#x00025; SDS, and protease inhibitor mixture (Roche Diagnostics).</p><p>Thirty &#x000b5;g of protein was run on a NuPAGE 4&#x02013;12&#x00025; Bis-Tris gel (Invitrogen). Total protein was transferred to a nitrocellulose membrane (Schleicher and Schuell BioScience, Inc., Keene, NH) and was subsequently immunoblotted for the protein of interest. The membrane was blocked overnight at 4&#x000b0;C, which was followed by incubation with protein specific primary antibody for 2 to 3 hr at room temperature. After incubation with a secondary antibody conjugated to HRP (horseradish peroxidase) (Amersham Biosciences, Piscataway, NJ) for 1 hr at room temperature, the membrane was developed using a SuperSignal West Pico Chemiluminescent Substrate (Pierce Biotechnology, Inc., Rockford, IL) and exposed to X-OMAT film (Kodak).</p></sec><sec id="s4e"><title>DNA microarray</title><p>Cells were cultured in media containing 0.5&#x00025; FBS (for PGE<sub>2</sub>, S1P and nicotinic acid) or 10&#x00025; FBS (for LPS, Pam<sub>2</sub>, Pam<sub>3</sub>, CpG, zymosan and polyIC) for 18 hr; stimulated with an agonist for 30 min, 2 hr or 4 hr; and were then harvested with Trizol (Invitrogen, Carlsbad, CA). Cells for the basic RNAi tool tests of siRNA, shRNA or ASO were cultured in media containing 10&#x00025; FBS and were harvested with Trizol. Three micrograms of total RNAs from the cells were used as the starting material for the microarray analysis.</p><p>The 16K mouse oligonucleotide arrays were fabricated using an inkjet-printing method by Agilent Technologies (Palo Alto, CA). These oligo arrays includes 13,536 probes of 70mers (Operon Technologies Inc., Alameda, CA) and 2,304 probes of 65mers (Sigma-Genosys, The Woodlands, TX). The platform description (platform accession number GPL254) is available at GEO (Gene Expression Omnibus: <ext-link ext-link-type="uri" xlink:href="http://www.ncbi.nlm.nih.gov/projects/geo/">http://www.ncbi.nlm.nih.gov/projects/geo/</ext-link>). The aminoallyl method was utilized for the preparation of the fluorescently labeled target samples.</p></sec><sec id="s4f"><title>Quantitative RT-PCR</title><p>Quantitative real-time RT-PCR was performed using iCycler (Bio-Rad Laboratories, Inc., Hercules, CA) following the manufacturer's protocol. The measurement was normalized to a &#x003b2; actin RNA control. The primers of genes are as follows: Nfkbiz, F <named-content content-type="gene">5&#x02032;-CGA TGG ACC GGT TTG CA-3&#x02032;</named-content>, R <named-content content-type="gene">5&#x02032;-GTA GGC GTT TGC GGT GAT G-3&#x02032;</named-content>; Egr-2, F <named-content content-type="gene">5&#x02032;-GTG CCA GCT GCT ATC CAG AAG</named-content>, R <named-content content-type="gene">5&#x02032;-GGC TGT GGT TGA AGC TGG AG-3&#x02032;</named-content>; TNF, F <named-content content-type="gene">5&#x02032;-CCC TCA CAC TCA GAT CAT CTT CT-3&#x02032;</named-content>, R <named-content content-type="gene">5&#x02032;-GCT ACG ACG TGG GCT ACA G-3&#x02032;</named-content>; &#x003b2;-actin, F <named-content content-type="gene">5&#x02032;-CTT TGC AGC TCC TTC GTT GC-3&#x02032;</named-content>, R <named-content content-type="gene">5&#x02032;-ACG ATG GAG GGG AAT ACA GC-3&#x02032;</named-content>. The remaining primer sequences are available upon request.</p></sec></sec><sec sec-type="supplementary-material" id="s5"><title>Supporting Information</title><supplementary-material content-type="local-data" id="pone.0004559.s001"><label>Table S1</label><caption><p>Expression of selected signaling genes in RAW 264.7 cells, as assessed by Affymetrix GeneChips and RT-PCR. There were multiple probe sets in some cases. U: unavailable, P: present, A: absent, M: marginal.</p><p>(0.04 MB XLS)</p></caption><media xlink:href="pone.0004559.s001.xls" mimetype="application" mime-subtype="vnd.ms-excel"><caption><p>Click here for additional data file.</p></caption></media></supplementary-material><supplementary-material content-type="local-data" id="pone.0004559.s002"><label>Table S2</label><caption><p>mRNA expression levels (log<sub>2</sub> ratio) of G protein subunits assessed by DNA microarrays in shRNA, siRNA and ASO-treated RAW 264.7 cells.</p><p>(0.05 MB XLS)</p></caption><media xlink:href="pone.0004559.s002.xls" mimetype="application" mime-subtype="vnd.ms-excel"><caption><p>Click here for additional data file.</p></caption></media></supplementary-material></sec></body><back><ack><p>The authors would like to thank the members of The Alliance for Cellular Signaling (<ext-link ext-link-type="uri" xlink:href="http://www.signaling-gateway.org/">http://www.signaling-gateway.org/</ext-link>, Alliance for Cellular Signaling) for their assistance.</p></ack><ref-list><title>References</title><ref id="pone.0004559-Guo1"><label>1</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Guo</surname><given-names>S</given-names></name><name><surname>Kemphues</surname><given-names>KJ</given-names></name></person-group><year>1995</year><article-title>par-1, a gene required for establishing polarity in C. elegans embryos, encodes a putative Ser/Thr kinase that is asymmetrically distributed.</article-title><source>Cell</source><volume>81</volume><fpage>611</fpage><lpage>620</lpage><pub-id pub-id-type="pmid">7758115</pub-id></citation></ref><ref id="pone.0004559-Hannon1"><label>2</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Hannon</surname><given-names>GJ</given-names></name></person-group><year>2002</year><article-title>RNA interference.</article-title><source>Nature</source><volume>418</volume><fpage>244</fpage><lpage>251</lpage><pub-id pub-id-type="pmid">12110901</pub-id></citation></ref><ref id="pone.0004559-Hutvagner1"><label>3</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Hutvagner</surname><given-names>G</given-names></name><name><surname>Zamore</surname><given-names>PD</given-names></name></person-group><year>2002</year><article-title>RNAi: nature abhors a double-strand.</article-title><source>Current Opinion in Genetics &#x00026; Development</source><volume>12</volume><fpage>225</fpage><lpage>232</lpage><pub-id pub-id-type="pmid">11893497</pub-id></citation></ref><ref id="pone.0004559-Sharp1"><label>4</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Sharp</surname><given-names>PA</given-names></name></person-group><year>1999</year><article-title>RNAi and double-strand RNA.</article-title><source>Genes &#x00026; Development</source><volume>13</volume><fpage>139</fpage><lpage>141</lpage><pub-id pub-id-type="pmid">9925636</pub-id></citation></ref><ref id="pone.0004559-Hwang1"><label>5</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Hwang</surname><given-names>JI</given-names></name><name><surname>Fraser</surname><given-names>ID</given-names></name><name><surname>Choi</surname><given-names>S</given-names></name><name><surname>Qin</surname><given-names>XF</given-names></name><name><surname>Simon</surname><given-names>MI</given-names></name></person-group><year>2004</year><article-title>Analysis of C5a-mediated chemotaxis by lentiviral delivery of small interfering RNA.</article-title><source>Proc Natl Acad Sci U S A</source><volume>101</volume><fpage>488</fpage><lpage>493</lpage><pub-id pub-id-type="pmid">14699051</pub-id></citation></ref><ref id="pone.0004559-Hwang2"><label>6</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Hwang</surname><given-names>JI</given-names></name><name><surname>Choi</surname><given-names>S</given-names></name><name><surname>Fraser</surname><given-names>ID</given-names></name><name><surname>Chang</surname><given-names>MS</given-names></name><name><surname>Simon</surname><given-names>MI</given-names></name></person-group><year>2005</year><article-title>Silencing the expression of multiple G{beta}-subunits eliminates signaling mediated by all four families of G proteins.</article-title><source>Proc Natl Acad Sci U S A</source></citation></ref><ref id="pone.0004559-Mello1"><label>7</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Mello</surname><given-names>CC</given-names></name><name><surname>Conte</surname><given-names>D</given-names><suffix>Jr</suffix></name></person-group><year>2004</year><article-title>Revealing the world of RNA interference.</article-title><source>Nature</source><volume>431</volume><fpage>338</fpage><lpage>342</lpage><pub-id pub-id-type="pmid">15372040</pub-id></citation></ref><ref id="pone.0004559-Bernstein1"><label>8</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Bernstein</surname><given-names>E</given-names></name><name><surname>Caudy</surname><given-names>AA</given-names></name><name><surname>Hammond</surname><given-names>SM</given-names></name><name><surname>Hannon</surname><given-names>GJ</given-names></name></person-group><year>2001</year><article-title>Role for a bidentate ribonuclease in the initiation step of RNA interference.</article-title><source>Nature</source><volume>409</volume><fpage>363</fpage><lpage>366</lpage><pub-id pub-id-type="pmid">11201747</pub-id></citation></ref><ref id="pone.0004559-Bernstein2"><label>9</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Bernstein</surname><given-names>E</given-names></name><name><surname>Kim</surname><given-names>SY</given-names></name><name><surname>Carmell</surname><given-names>MA</given-names></name><name><surname>Murchison</surname><given-names>EP</given-names></name><name><surname>Alcorn</surname><given-names>H</given-names></name><etal/></person-group><year>2003</year><article-title>Dicer is essential for mouse development.</article-title><source>Nat Genet</source><volume>35</volume><fpage>215</fpage><lpage>217</lpage><pub-id pub-id-type="pmid">14528307</pub-id></citation></ref><ref id="pone.0004559-Alexopoulou1"><label>10</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Alexopoulou</surname><given-names>L</given-names></name><name><surname>Holt</surname><given-names>AC</given-names></name><name><surname>Medzhitov</surname><given-names>R</given-names></name><name><surname>Flavell</surname><given-names>RA</given-names></name></person-group><year>2001</year><article-title>Recognition of double-stranded RNA and activation of NF-kappaB by Toll-like receptor 3.</article-title><source>Nature</source><volume>413</volume><fpage>732</fpage><lpage>738</lpage><pub-id pub-id-type="pmid">11607032</pub-id></citation></ref><ref id="pone.0004559-Heil1"><label>11</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Heil</surname><given-names>F</given-names></name><name><surname>Hemmi</surname><given-names>H</given-names></name><name><surname>Hochrein</surname><given-names>H</given-names></name><name><surname>Ampenberger</surname><given-names>F</given-names></name><name><surname>Kirschning</surname><given-names>C</given-names></name><etal/></person-group><year>2004</year><article-title>Species-specific recognition of single-stranded RNA via toll-like receptor 7 and 8.</article-title><source>Science</source><volume>303</volume><fpage>1526</fpage><lpage>1529</lpage><pub-id pub-id-type="pmid">14976262</pub-id></citation></ref><ref id="pone.0004559-Lund1"><label>12</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Lund</surname><given-names>JM</given-names></name><name><surname>Alexopoulou</surname><given-names>L</given-names></name><name><surname>Sato</surname><given-names>A</given-names></name><name><surname>Karow</surname><given-names>M</given-names></name><name><surname>Adams</surname><given-names>NC</given-names></name><etal/></person-group><year>2004</year><article-title>Recognition of single-stranded RNA viruses by Toll-like receptor 7.</article-title><source>Proc Natl Acad Sci U S A</source><volume>101</volume><fpage>5598</fpage><lpage>5603</lpage><pub-id pub-id-type="pmid">15034168</pub-id></citation></ref><ref id="pone.0004559-Diebold1"><label>13</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Diebold</surname><given-names>SS</given-names></name><name><surname>Kaisho</surname><given-names>T</given-names></name><name><surname>Hemmi</surname><given-names>H</given-names></name><name><surname>Akira</surname><given-names>S</given-names></name><name><surname>Reis e Sousa</surname><given-names>C</given-names></name></person-group><year>2004</year><article-title>Innate antiviral responses by means of TLR7-mediated recognition of single-stranded RNA.</article-title><source>Science</source><volume>303</volume><fpage>1529</fpage><lpage>1531</lpage><pub-id pub-id-type="pmid">14976261</pub-id></citation></ref><ref id="pone.0004559-Judge1"><label>14</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Judge</surname><given-names>AD</given-names></name><name><surname>Sood</surname><given-names>V</given-names></name><name><surname>Shaw</surname><given-names>JR</given-names></name><name><surname>Fang</surname><given-names>D</given-names></name><name><surname>McClintock</surname><given-names>K</given-names></name><etal/></person-group><year>2005</year><article-title>Sequence-dependent stimulation of the mammalian innate immune response by synthetic siRNA.</article-title><source>Nat Biotechnol</source><volume>23</volume><fpage>457</fpage><lpage>462</lpage><pub-id pub-id-type="pmid">15778705</pub-id></citation></ref><ref id="pone.0004559-Kariko1"><label>15</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Kariko</surname><given-names>K</given-names></name><name><surname>Bhuyan</surname><given-names>P</given-names></name><name><surname>Capodici</surname><given-names>J</given-names></name><name><surname>Weissman</surname><given-names>D</given-names></name></person-group><year>2004</year><article-title>Small interfering RNAs mediate sequence-independent gene suppression and induce immune activation by signaling through toll-like receptor 3.</article-title><source>J Immunol</source><volume>172</volume><fpage>6545</fpage><lpage>6549</lpage><pub-id pub-id-type="pmid">15153468</pub-id></citation></ref><ref id="pone.0004559-Kleinman1"><label>16</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Kleinman</surname><given-names>ME</given-names></name><name><surname>Yamada</surname><given-names>K</given-names></name><name><surname>Takeda</surname><given-names>A</given-names></name><name><surname>Chandrasekaran</surname><given-names>V</given-names></name><name><surname>Nozaki</surname><given-names>M</given-names></name><etal/></person-group><year>2008</year><article-title>Sequence- and target-independent angiogenesis suppression by siRNA via TLR3.</article-title><source>Nature</source><volume>452</volume><fpage>591</fpage><lpage>597</lpage><pub-id pub-id-type="pmid">18368052</pub-id></citation></ref><ref id="pone.0004559-Grishina1"><label>17</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Grishina</surname><given-names>G</given-names></name><name><surname>Berlot</surname><given-names>CH</given-names></name></person-group><year>1997</year><article-title>Identification of common and distinct residues involved in the interaction of alphai2 and alphas with adenylyl cyclase.</article-title><source>Journal of Biological Chemistry</source><volume>272</volume><fpage>20619</fpage><lpage>20626</lpage><pub-id pub-id-type="pmid">9252377</pub-id></citation></ref><ref id="pone.0004559-Rudolph1"><label>18</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Rudolph</surname><given-names>U</given-names></name><name><surname>Finegold</surname><given-names>MJ</given-names></name><name><surname>Rich</surname><given-names>SS</given-names></name><name><surname>Harriman</surname><given-names>GR</given-names></name><name><surname>Srinivasan</surname><given-names>Y</given-names></name><etal/></person-group><year>1995</year><article-title>Gi2 alpha protein deficiency: a model of inflammatory bowel disease.</article-title><source>Journal of Clinical Immunology</source><volume>15</volume><fpage>101S</fpage><lpage>105S</lpage><pub-id pub-id-type="pmid">8613481</pub-id></citation></ref><ref id="pone.0004559-Pace1"><label>19</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Pace</surname><given-names>AM</given-names></name><name><surname>Faure</surname><given-names>M</given-names></name><name><surname>Bourne</surname><given-names>HR</given-names></name></person-group><year>1995</year><article-title>Gi2-mediated activation of the MAP kinase cascade.</article-title><source>Mol Biol Cell</source><volume>6</volume><fpage>1685</fpage><lpage>1695</lpage><pub-id pub-id-type="pmid">8590798</pub-id></citation></ref><ref id="pone.0004559-Huang1"><label>20</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Huang</surname><given-names>TT</given-names></name><name><surname>Zong</surname><given-names>Y</given-names></name><name><surname>Dalwadi</surname><given-names>H</given-names></name><name><surname>Chung</surname><given-names>C</given-names></name><name><surname>Miceli</surname><given-names>MC</given-names></name><etal/></person-group><year>2003</year><article-title>TCR-mediated hyper-responsiveness of autoimmune Galphai2(&#x02212;/&#x02212;) mice is an intrinsic naive CD4(&#x0002b;) T cell disorder selective for the Galphai2 subunit.</article-title><source>Int Immunol</source><volume>15</volume><fpage>1359</fpage><lpage>1367</lpage><pub-id pub-id-type="pmid">14565934</pub-id></citation></ref><ref id="pone.0004559-Lyons1"><label>21</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Lyons</surname><given-names>J</given-names></name><name><surname>Landis</surname><given-names>CA</given-names></name><name><surname>Harsh</surname><given-names>G</given-names></name><name><surname>Vallar</surname><given-names>L</given-names></name><name><surname>Grunewald</surname><given-names>K</given-names></name><etal/></person-group><year>1990</year><article-title>Two G protein oncogenes in human endocrine tumors.</article-title><source>Science</source><volume>249</volume><fpage>655</fpage><lpage>659</lpage><pub-id pub-id-type="pmid">2116665</pub-id></citation></ref><ref id="pone.0004559-Sprang1"><label>22</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Sprang</surname><given-names>SR</given-names></name></person-group><year>1997</year><article-title>G protein mechanisms: insights from structural analysis.</article-title><source>Annual Review of Biochemistry</source><volume>66</volume><fpage>639</fpage><lpage>678</lpage></citation></ref><ref id="pone.0004559-Watkins1"><label>23</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Watkins</surname><given-names>DC</given-names></name><name><surname>Johnson</surname><given-names>GL</given-names></name><name><surname>Malbon</surname><given-names>CC</given-names></name></person-group><year>1992</year><article-title>Regulation of the differentiation of teratocarcinoma cells into primitive endoderm by G alpha i2.</article-title><source>Science</source><volume>258</volume><fpage>1373</fpage><lpage>1375</lpage><pub-id pub-id-type="pmid">1455234</pub-id></citation></ref><ref id="pone.0004559-Zhang1"><label>24</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>Y</given-names></name><name><surname>Finegold</surname><given-names>MJ</given-names></name><name><surname>Jin</surname><given-names>Y</given-names></name><name><surname>Wu</surname><given-names>MX</given-names></name></person-group><year>2005</year><article-title>Accelerated transition from the double-positive to single-positive thymocytes in G alpha i2-deficient mice.</article-title><source>Int Immunol</source><volume>17</volume><fpage>233</fpage><lpage>243</lpage><pub-id pub-id-type="pmid">15684040</pub-id></citation></ref><ref id="pone.0004559-Bjursten1"><label>25</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Bjursten</surname><given-names>M</given-names></name><name><surname>Hultgren Hornquist</surname><given-names>E</given-names></name></person-group><year>2005</year><article-title>Dietary antigen-specific T-cell responses: switch from an interleukin-10-dominated response in normal mice to a T-helper 1 cytokine profile in Galphai2-deficient mice prior to colitis.</article-title><source>Scandinavian Journal of Immunology</source><volume>61</volume><fpage>29</fpage><lpage>35</lpage><pub-id pub-id-type="pmid">15644120</pub-id></citation></ref><ref id="pone.0004559-Bjursten2"><label>26</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Bjursten</surname><given-names>M</given-names></name><name><surname>Hultgren</surname><given-names>OH</given-names></name><name><surname>Hultgren Hornquist</surname><given-names>E</given-names></name></person-group><year>2004</year><article-title>Enhanced pro-inflammatory cytokine production in Galphai2-deficient mice on colitis prone and colitis resistant 129Sv genetic backgrounds.</article-title><source>Cellular Immunology</source><volume>228</volume><fpage>77</fpage><lpage>80</lpage><pub-id pub-id-type="pmid">15219458</pub-id></citation></ref><ref id="pone.0004559-Baritono1"><label>27</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Baritono</surname><given-names>E</given-names></name><name><surname>Ceolotto</surname><given-names>G</given-names></name><name><surname>Papparella</surname><given-names>I</given-names></name><name><surname>Sartori</surname><given-names>M</given-names></name><name><surname>Ciccariello</surname><given-names>L</given-names></name><etal/></person-group><year>2004</year><article-title>Abnormal regulation of G protein alpha(i2) subunit in skin fibroblasts from insulin-resistant hypertensive individuals.</article-title><source>J Hypertens</source><volume>22</volume><fpage>783</fpage><lpage>792</lpage><pub-id pub-id-type="pmid">15126921</pub-id></citation></ref><ref id="pone.0004559-Stewart1"><label>28</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Stewart</surname><given-names>SA</given-names></name><name><surname>Dykxhoorn</surname><given-names>DM</given-names></name><name><surname>Palliser</surname><given-names>D</given-names></name><name><surname>Mizuno</surname><given-names>H</given-names></name><name><surname>Yu</surname><given-names>EY</given-names></name><etal/></person-group><year>2003</year><article-title>Lentivirus-delivered stable gene silencing by RNAi in primary cells.</article-title><source>Rna-A Publication of the Rna Society</source><volume>9</volume><fpage>493</fpage><lpage>501</lpage></citation></ref><ref id="pone.0004559-Kim1"><label>29</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Kim</surname><given-names>DH</given-names></name><name><surname>Behlke</surname><given-names>MA</given-names></name><name><surname>Rose</surname><given-names>SD</given-names></name><name><surname>Chang</surname><given-names>MS</given-names></name><name><surname>Choi</surname><given-names>S</given-names></name><etal/></person-group><year>2005</year><article-title>Synthetic dsRNA Dicer substrates enhance RNAi potency and efficacy.</article-title><source>Nat Biotechnol</source><volume>23</volume><fpage>222</fpage><lpage>226</lpage><pub-id pub-id-type="pmid">15619617</pub-id></citation></ref><ref id="pone.0004559-Overhoff1"><label>30</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Overhoff</surname><given-names>M</given-names></name><name><surname>Alken</surname><given-names>M</given-names></name><name><surname>Far</surname><given-names>RK</given-names></name><name><surname>Lemaitre</surname><given-names>M</given-names></name><name><surname>Lebleu</surname><given-names>B</given-names></name><etal/></person-group><year>2005</year><article-title>Local RNA target structure influences siRNA efficacy: a systematic global analysis.</article-title><source>J Mol Biol</source><volume>348</volume><fpage>871</fpage><lpage>881</lpage><pub-id pub-id-type="pmid">15843019</pub-id></citation></ref><ref id="pone.0004559-Song1"><label>31</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Song</surname><given-names>E</given-names></name><name><surname>Lee</surname><given-names>SK</given-names></name><name><surname>Dykxhoorn</surname><given-names>DM</given-names></name><name><surname>Novina</surname><given-names>C</given-names></name><name><surname>Zhang</surname><given-names>D</given-names></name><etal/></person-group><year>2003</year><article-title>Sustained small interfering RNA-mediated human immunodeficiency virus type 1 inhibition in primary macrophages.</article-title><source>J Virol</source><volume>77</volume><fpage>7174</fpage><lpage>7181</lpage><pub-id pub-id-type="pmid">12805416</pub-id></citation></ref><ref id="pone.0004559-Endesfelder1"><label>32</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Endesfelder</surname><given-names>S</given-names></name><name><surname>Kliche</surname><given-names>A</given-names></name><name><surname>Lochmuller</surname><given-names>H</given-names></name><name><surname>von Moers</surname><given-names>A</given-names></name><name><surname>Speer</surname><given-names>A</given-names></name></person-group><year>2005</year><article-title>Antisense oligonucleotides and short interfering RNAs silencing the cyclin-dependent kinase inhibitor p21 improve proliferation of Duchenne muscular dystrophy patients' primary skeletal myoblasts.</article-title><source>J Mol Med</source><volume>83</volume><fpage>64</fpage><lpage>71</lpage><pub-id pub-id-type="pmid">15536518</pub-id></citation></ref><ref id="pone.0004559-Yin1"><label>33</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Yin</surname><given-names>C</given-names></name><name><surname>Xi</surname><given-names>L</given-names></name><name><surname>Wang</surname><given-names>X</given-names></name><name><surname>Eapen</surname><given-names>M</given-names></name><name><surname>Kukreja</surname><given-names>RC</given-names></name></person-group><year>2005</year><article-title>Silencing heat shock factor 1 by small interfering RNA abrogates heat shock-induced cardioprotection against ischemia-reperfusion injury in mice.</article-title><source>J Mol Cell Cardiol</source></citation></ref><ref id="pone.0004559-Kim2"><label>34</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Kim</surname><given-names>DH</given-names></name><name><surname>Longo</surname><given-names>M</given-names></name><name><surname>Han</surname><given-names>Y</given-names></name><name><surname>Lundberg</surname><given-names>P</given-names></name><name><surname>Cantin</surname><given-names>E</given-names></name><etal/></person-group><year>2004</year><article-title>Interferon induction by siRNAs and ssRNAs synthesized by phage polymerase.</article-title><source>Nat Biotechnol</source><volume>22</volume><fpage>321</fpage><lpage>325</lpage><pub-id pub-id-type="pmid">14990954</pub-id></citation></ref><ref id="pone.0004559-Pichlmair1"><label>35</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Pichlmair</surname><given-names>A</given-names></name><name><surname>Schulz</surname><given-names>O</given-names></name><name><surname>Tan</surname><given-names>CP</given-names></name><name><surname>Naslund</surname><given-names>TI</given-names></name><name><surname>Liljestrom</surname><given-names>P</given-names></name><etal/></person-group><year>2006</year><article-title>RIG-I-mediated antiviral responses to single-stranded RNA bearing 5&#x02032;-phosphates.</article-title><source>Science</source><volume>314</volume><fpage>997</fpage><lpage>1001</lpage><pub-id pub-id-type="pmid">17038589</pub-id></citation></ref><ref id="pone.0004559-Hornung1"><label>36</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Hornung</surname><given-names>V</given-names></name><name><surname>Ellegast</surname><given-names>J</given-names></name><name><surname>Kim</surname><given-names>S</given-names></name><name><surname>Brzozka</surname><given-names>K</given-names></name><name><surname>Jung</surname><given-names>A</given-names></name><etal/></person-group><year>2006</year><article-title>5&#x02032;-Triphosphate RNA is the ligand for RIG-I.</article-title><source>Science</source><volume>314</volume><fpage>994</fpage><lpage>997</lpage><pub-id pub-id-type="pmid">17038590</pub-id></citation></ref><ref id="pone.0004559-Krieg1"><label>37</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Krieg</surname><given-names>AM</given-names></name></person-group><year>2002</year><article-title>CpG motifs in bacterial DNA and their immune effects.</article-title><source>Annu Rev Immunol</source><volume>20</volume><fpage>709</fpage><lpage>760</lpage><pub-id pub-id-type="pmid">11861616</pub-id></citation></ref><ref id="pone.0004559-Yi1"><label>38</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Yi</surname><given-names>AK</given-names></name><name><surname>Yoon</surname><given-names>JG</given-names></name><name><surname>Yeo</surname><given-names>SJ</given-names></name><name><surname>Hong</surname><given-names>SC</given-names></name><name><surname>English</surname><given-names>BK</given-names></name><etal/></person-group><year>2002</year><article-title>Role of mitogen-activated protein kinases in CpG DNA-mediated IL-10 and IL-12 production: central role of extracellular signal-regulated kinase in the negative feedback loop of the CpG DNA-mediated Th1 response.</article-title><source>J Immunol</source><volume>168</volume><fpage>4711</fpage><lpage>4720</lpage><pub-id pub-id-type="pmid">11971021</pub-id></citation></ref><ref id="pone.0004559-Stovall1"><label>39</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Stovall</surname><given-names>SH</given-names></name><name><surname>Yi</surname><given-names>AK</given-names></name><name><surname>Meals</surname><given-names>EA</given-names></name><name><surname>Talati</surname><given-names>AJ</given-names></name><name><surname>Godambe</surname><given-names>SA</given-names></name><etal/></person-group><year>2004</year><article-title>Role of vav1- and src-related tyrosine kinases in macrophage activation by CpG DNA.</article-title><source>J Biol Chem</source><volume>279</volume><fpage>13809</fpage><lpage>13816</lpage><pub-id pub-id-type="pmid">14749335</pub-id></citation></ref><ref id="pone.0004559-Yeo1"><label>40</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Yeo</surname><given-names>SJ</given-names></name><name><surname>Gravis</surname><given-names>D</given-names></name><name><surname>Yoon</surname><given-names>JG</given-names></name><name><surname>Yi</surname><given-names>AK</given-names></name></person-group><year>2003</year><article-title>Myeloid differentiation factor 88-dependent transcriptional regulation of cyclooxygenase-2 expression by CpG DNA: role of NF-kappaB and p38.</article-title><source>J Biol Chem</source><volume>278</volume><fpage>22563</fpage><lpage>22573</lpage><pub-id pub-id-type="pmid">12695520</pub-id></citation></ref><ref id="pone.0004559-Yeo2"><label>41</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Yeo</surname><given-names>SJ</given-names></name><name><surname>Yoon</surname><given-names>JG</given-names></name><name><surname>Yi</surname><given-names>AK</given-names></name></person-group><year>2003</year><article-title>Myeloid differentiation factor 88-dependent post-transcriptional regulation of cyclooxygenase-2 expression by CpG DNA: tumor necrosis factor-alpha receptor-associated factor 6, a diverging point in the Toll-like receptor 9-signaling.</article-title><source>J Biol Chem</source><volume>278</volume><fpage>40590</fpage><lpage>40600</lpage><pub-id pub-id-type="pmid">12902324</pub-id></citation></ref><ref id="pone.0004559-Wang1"><label>42</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>Q</given-names></name><name><surname>Mullah</surname><given-names>BK</given-names></name><name><surname>Robishaw</surname><given-names>JD</given-names></name></person-group><year>1999</year><article-title>Ribozyme approach identifies a functional association between the G protein beta1gamma7 subunits in the beta-adrenergic receptor signaling pathway.</article-title><source>Journal of Biological Chemistry</source><volume>274</volume><fpage>17365</fpage><lpage>17371</lpage><pub-id pub-id-type="pmid">10358098</pub-id></citation></ref><ref id="pone.0004559-Jackson1"><label>43</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Jackson</surname><given-names>AL</given-names></name><name><surname>Bartz</surname><given-names>SR</given-names></name><name><surname>Schelter</surname><given-names>J</given-names></name><name><surname>Kobayashi</surname><given-names>SV</given-names></name><name><surname>Burchard</surname><given-names>J</given-names></name><etal/></person-group><year>2003</year><article-title>Expression profiling reveals off-target gene regulation by RNAi.</article-title><source>Nature Biotechnology</source><volume>21</volume><fpage>635</fpage><lpage>637</lpage></citation></ref><ref id="pone.0004559-Mao1"><label>44</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Mao</surname><given-names>H</given-names></name><name><surname>Zhao</surname><given-names>Q</given-names></name><name><surname>Daigle</surname><given-names>M</given-names></name><name><surname>Ghahremani</surname><given-names>MH</given-names></name><name><surname>Chidiac</surname><given-names>P</given-names></name><etal/></person-group><year>2004</year><article-title>RGS17/RGSZ2, a novel regulator of Gi/o, Gz, and Gq signaling.</article-title><source>J Biol Chem</source><volume>279</volume><fpage>26314</fpage><lpage>26322</lpage><pub-id pub-id-type="pmid">15096504</pub-id></citation></ref><ref id="pone.0004559-Akira1"><label>45</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Akira</surname><given-names>S</given-names></name><name><surname>Takeda</surname><given-names>K</given-names></name><name><surname>Kaisho</surname><given-names>T</given-names></name></person-group><year>2001</year><article-title>Toll-like receptors: critical proteins linking innate and acquired immunity.</article-title><source>Nat Immunol</source><volume>2</volume><fpage>675</fpage><lpage>680</lpage><pub-id pub-id-type="pmid">11477402</pub-id></citation></ref><ref id="pone.0004559-Yamamoto1"><label>46</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Yamamoto</surname><given-names>M</given-names></name><name><surname>Sato</surname><given-names>S</given-names></name><name><surname>Hemmi</surname><given-names>H</given-names></name><name><surname>Uematsu</surname><given-names>S</given-names></name><name><surname>Hoshino</surname><given-names>K</given-names></name><etal/></person-group><year>2003</year><article-title>TRAM is specifically involved in the Toll-like receptor 4-mediated MyD88-independent signaling pathway.</article-title><source>Nat Immunol</source><volume>4</volume><fpage>1144</fpage><lpage>1150</lpage><pub-id pub-id-type="pmid">14556004</pub-id></citation></ref><ref id="pone.0004559-Krishnan1"><label>47</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Krishnan</surname><given-names>J</given-names></name><name><surname>Selvarajoo</surname><given-names>K</given-names></name><name><surname>Tsuchiya</surname><given-names>M</given-names></name><name><surname>Lee</surname><given-names>G</given-names></name><name><surname>Choi</surname><given-names>S</given-names></name></person-group><year>2007</year><article-title>Toll-like receptor signal transduction.</article-title><source>Exp Mol Med</source><volume>39</volume><fpage>421</fpage><lpage>438</lpage><pub-id pub-id-type="pmid">17934330</pub-id></citation></ref><ref id="pone.0004559-Takeda1"><label>48</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Takeda</surname><given-names>K</given-names></name><name><surname>Kaisho</surname><given-names>T</given-names></name><name><surname>Akira</surname><given-names>S</given-names></name></person-group><year>2003</year><article-title>Toll-like receptors.</article-title><source>Annu Rev Immunol</source><volume>21</volume><fpage>335</fpage><lpage>376</lpage><pub-id pub-id-type="pmid">12524386</pub-id></citation></ref><ref id="pone.0004559-Castanotto1"><label>49</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Castanotto</surname><given-names>D</given-names></name><name><surname>Sakurai</surname><given-names>K</given-names></name><name><surname>Lingeman</surname><given-names>R</given-names></name><name><surname>Li</surname><given-names>H</given-names></name><name><surname>Shively</surname><given-names>L</given-names></name><etal/></person-group><year>2007</year><article-title>Combinatorial delivery of small interfering RNAs reduces RNAi efficacy by selective incorporation into RISC.</article-title><source>Nucleic Acids Res</source><volume>35</volume><fpage>5154</fpage><lpage>5164</lpage><pub-id pub-id-type="pmid">17660190</pub-id></citation></ref><ref id="pone.0004559-Tafer1"><label>50</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Tafer</surname><given-names>H</given-names></name><name><surname>Ameres</surname><given-names>SL</given-names></name><name><surname>Obernosterer</surname><given-names>G</given-names></name><name><surname>Gebeshuber</surname><given-names>CA</given-names></name><name><surname>Schroeder</surname><given-names>R</given-names></name><etal/></person-group><year>2008</year><article-title>The impact of target site accessibility on the design of effective siRNAs.</article-title><source>Nat Biotechnol</source><volume>26</volume><fpage>578</fpage><lpage>583</lpage><pub-id pub-id-type="pmid">18438400</pub-id></citation></ref><ref id="pone.0004559-Koller1"><label>51</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Koller</surname><given-names>E</given-names></name><name><surname>Propp</surname><given-names>S</given-names></name><name><surname>Murray</surname><given-names>H</given-names></name><name><surname>Lima</surname><given-names>W</given-names></name><name><surname>Bhat</surname><given-names>B</given-names></name><etal/></person-group><year>2006</year><article-title>Competition for RISC binding predicts in vitro potency of siRNA.</article-title><source>Nucleic Acids Res</source><volume>34</volume><fpage>4467</fpage><lpage>4476</lpage><pub-id pub-id-type="pmid">16945958</pub-id></citation></ref><ref id="pone.0004559-Siolas1"><label>52</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Siolas</surname><given-names>D</given-names></name><name><surname>Lerner</surname><given-names>C</given-names></name><name><surname>Burchard</surname><given-names>J</given-names></name><name><surname>Ge</surname><given-names>W</given-names></name><name><surname>Linsley</surname><given-names>PS</given-names></name><etal/></person-group><year>2005</year><article-title>Synthetic shRNAs as potent RNAi triggers.</article-title><source>Nat Biotechnol</source><volume>23</volume><fpage>227</fpage><lpage>231</lpage><pub-id pub-id-type="pmid">15619616</pub-id></citation></ref><ref id="pone.0004559-Hornquist1"><label>53</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Hornquist</surname><given-names>CE</given-names></name><name><surname>Lu</surname><given-names>X</given-names></name><name><surname>Rogers-Fani</surname><given-names>PM</given-names></name><name><surname>Rudolph</surname><given-names>U</given-names></name><name><surname>Shappell</surname><given-names>S</given-names></name><etal/></person-group><year>1997</year><article-title>G(alpha)i2-deficient mice with colitis exhibit a local increase in memory CD4&#x0002b; T cells and proinflammatory Th1-type cytokines.</article-title><source>Journal of Immunology</source><volume>158</volume><fpage>1068</fpage><lpage>1077</lpage></citation></ref><ref id="pone.0004559-Fan1"><label>54</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Fan</surname><given-names>H</given-names></name><name><surname>Zingarelli</surname><given-names>B</given-names></name><name><surname>Peck</surname><given-names>OM</given-names></name><name><surname>Teti</surname><given-names>G</given-names></name><name><surname>Tempel</surname><given-names>GE</given-names></name><etal/></person-group><year>2005</year><article-title>Lipopolysaccharide and Gram-positive Bacteria Induced Cellular Inflammatory Responses: Role of Heterotrimeric G{alpha}i Proteins.</article-title><source>Am J Physiol Cell Physiol</source></citation></ref><ref id="pone.0004559-Salmon1"><label>55</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Salmon</surname><given-names>P</given-names></name><name><surname>Kindler</surname><given-names>V</given-names></name><name><surname>Ducrey</surname><given-names>O</given-names></name><name><surname>Chapuis</surname><given-names>B</given-names></name><name><surname>Zubler</surname><given-names>RH</given-names></name><etal/></person-group><year>2000</year><article-title>High-level transgene expression in human hematopoietic progenitors and differentiated blood lineages after transduction with improved lentiviral vectors.</article-title><source>Blood</source><volume>96</volume><fpage>3392</fpage><lpage>3398</lpage><pub-id pub-id-type="pmid">11071633</pub-id></citation></ref></ref-list><fn-group><fn fn-type="conflict"><p><bold>Competing Interests: </bold>The authors have declared that no competing interests exist.</p></fn><fn fn-type="financial-disclosure"><p><bold>Funding: </bold>This work was supported by a Korea Science and Engineering Foundation (KOSEF) grant funded by the Korean Government (MOST) (R01-2007-000-20533-0). This work was also partly supported by a Korea Research Foundation Grant funded by the Korean Government (MOEHRD) (KRF-2006-311-C00482) and by the Ajou University Research Fellowship of 2008. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.</p></fn></fn-group></back></article>